

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2003290673 B2**

- (54) Title
Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
- (51) International Patent Classification(s)
C07C 323/25 (2006.01) **C07D 211/56** (2006.01)
C07C 323/41 (2006.01) **C07D 211/58** (2006.01)
C07D 211/14 (2006.01) **C07F 13/00** (2006.01)
C07D 211/52 (2006.01)
- (21) Application No: **2003290673** (22) Date of Filing: **2003.11.08**
- (87) WIPO No: **WO04/043380**
- (30) Priority Data
- (31) Number (32) Date (33) Country
60/424,980 **2002.11.08** **US**
- (43) Publication Date: **2004.06.03**
(43) Publication Journal Date: **2004.07.08**
(44) Accepted Journal Date: **2011.01.06**
- (71) Applicant(s)
Massachusetts Institute of Technology; President and Fellows of Harvard College
- (72) Inventor(s)
Davison, Alan; Cheng, Zheng Hoi; Jones, Alun G.; Mahmood, Ashfaq
- (74) Agent / Attorney
Pizzeys Patent and Trade Mark Attorneys, Level 14, ANZ Centre 324 Queen Street, Brisbane, QLD, 4000
- (56) Related Art
WO 1998 / 037055 A1; Papadopoulos et al, Nucl. Med. Biol., 20(1), 105-115 (1993); US 6 171 576 B1

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/043380 A3

(51) International Patent Classification⁷: **C07D 211/56**,
211/54, 211/52, 211/32, 211/18, C07C 211/13, A01N
33/02, 33/24, 37/18, 43/40

(74) Agents: **ALEXANDER, Ph. D., John, B.** et al.; Edwards
& Angell, LLP, P.O. Box 9169, Boston, MA 02209 (US).

(21) International Application Number:
PCT/US2003/035618

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
8 November 2003 (08.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
60/424,980 8 November 2002 (08.11.2002) US

(71) Applicants (*for all designated States except US*): **PRES-
IDENT AND FELLOWS OF HARVARD COLLEGE**
[US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
[US/US]; 5 Cambridge Center, Room NE 25-230, Kendall
Square, Cambridge, MA 02142-1493 (US).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MAHMOOD, Ash-
faq** [PK/US]; 161 Summer Street, Newton Center, MA
02459 (US). **CHENG, Zheng Hoi** [CN/US]; 2200 Cali-
fornia Street, Apt. 26, Mountain View, CA 94040 (US).
JONES, Alun, G. [GB/US]; 50 Manemet Road, Newton
Center, MA 02459 (US). **DAVISON, Alan** [US/US]; 190
Alder Lane, North Falmouth, MA 02556 (US).

(88) Date of publication of the international search report:
29 December 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 2004/043380 A3

(54) Title: SMALL TECHNETIUM-99M AND RHENIUM LABELED AGENTS AND METHODS FOR IMAGING TISSUES, ORGANS AND TUMORS

(57) Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors. In another embodiment, the invention relates the methods of imaging tissues, organs or tumors using radiolabeled metal complexes, particularly tissues, organs, or tumors which express certain receptors to which the compounds or complexes of the invention have an affinity. The present invention also relates to methods of treating cancer, particularly those cancer lines which express certain receptors to which the compounds or complexes of the invention have an affinity. In yet another embodiment, the present invention provides methods of imaging and/or inhibiting receptors or neuroreceptors using compounds or complexes of the invention which have an affinity for the receptor or neuroreceptor to be imaged and/or inhibited.

SMALL TECHNETIUM-99M AND RHENIUM LABELED AGENTS AND METHODS
FOR IMAGING TISSUES, ORGANS AND TUMORS

5 STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT

This invention was supported by National Institute of Health (NIH) Grant No. R37
CA34970. The United States government has certain rights to the invention.

10 This application claims the benefit of U.S. Provisional Patent Application
60/424,980, filed November 8, 2002, which application is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to small molecular radiometal diagnostic agents for
15 imaging tissues, particularly tissues expressing or overexpressing one or more receptors for
which the diagnostic agents of the invention have an affinity. More specifically, the present
invention relates to small molecular diagnostic agents for imaging tissues, which include
tumors, various brain tissues, and other organs and diseased states, bearing certain preferred
receptors and corresponding therapeutic complexes for treating the same. Preferred agents of
20 the invention includes technetium and rhenium complexes having a tertiary amine
pharmacophore linked to a chelating ligand. Typically preferred technetium and rhenium
complexes of the invention include those comprising a disubstituted piperidine group or a
tertiary amino group, which is substituted with at least one carbocyclic or heterocyclic
substituted alkyl group.

25

DEFINITION

In the specification the term "comprising" shall be understood to have a broad
meaning similar to the term "including" and will be understood to imply the inclusion of a
stated integer or step or group of integers or steps but not the exclusion of any other integer or
30 step or group of integers or steps. This definition also applies to variations on the term
"comprising" such as "comprise" and "comprises".

BACKGROUND OF THE INVENTION

Signal transduction in cells is defined as a biochemical communication from one part of the cell to another. Such communication between and within cells is carried out by, for
5 example, binding of an extracellular ligand to a specific cell surface transmembranal receptor which are coupled to G-proteins in the cytoplasm or by regulation of ion channels such as

Ca²⁺, Na⁺, K⁺, Cl⁻, or the like. Binding of the ligand to receptor induces a transmembranal signal which results in activation (or deactivation) of various cellular processes and functions. Small synthetic molecules that target these cellular receptors at the cell surface or intracellularly, with a high degree of specificity are highly desirable because of their rapid and increased tissue penetration, reduced immunogenicity and reduced metabolism when compared to monoclonal antibodies, their fragments or polypeptides.

The use of small molecules with gamma or positron emitting radiolabels also provides a means for non-invasive visualization and imaging of targeted receptors in both normal and diseased states. This has led to a search for small molecules labeled with positron emitting isotopes and single photon emitting isotopes that target various receptors and permit the non-invasive visualization of these receptors in the targeted tissues. See, for example, Nuclear Medicine Biology Vol 24, 485-498 1997. See also John (U.S. Patent 5,919, 934), Nuclear medicine Biology vol 28, 657-666 2001, and international publications to Mach (WO/0180905 A2 and WO 00/71171 A2).

Serotonin also known as 5-hydroxytryptamine (5-HT) is an important neurotransmitter molecule and various receptor subtypes have been identified, among these receptor subtypes 5HT_{1A} is one of the best characterized and studied as it is implicated in anxiety, depression, hallucinogenic behavior as well as in dementia such as Alzheimer's disease. See, for example, Neuropharmacology vol 38, 1083-1152 1999 and Euro.Journal of Nucl. Med. Vol 28, 113-129, 2001. A number of ^{99m}Tc-complexes with 2-methoxyphenylpiperazines have been investigated for binding and visualization of the 5HT_{1A} receptor, however no aryl-piperidine linked technetium or rhenium-complexes have been investigated or reported for this purpose. See, also Nuclear Medicine Biology Vol 24, 485-498 1997; Technetium, rhenium and other metals in chemistry and nuclear medicine 5. Padova: Servizi Grafici Editoriali, 1999:393-9; and European Journal of Nuclear Medicine vol 29(2) 263-275, 2002.

In addition to its role as a neurotransmitter, 5HT can also function as a growth factor and is found in most neuroendocrine cells of the human prostate and in human prostate cancer cell lines. Several articles have reviewed 5HT's role in prostate cancer cell lines, for example, Anticancer Res 1987;7:1-12; Cancer Res 1991;51:2498-2505; and Cancer

1992;70:254-68. A 5HT_{1A} receptor antagonist has also been shown to inhibit prostate tumor cell growth *in vivo* (Anticancer Res 1994; 14:1215-20).

5 Sigma-receptors are recognized to be intra-cellular cytoplasmatic sites, distinguished in at least σ -1 and σ -2 subtypes (with a σ -3 site also postulated). Both subtypes are widely distributed in CNS (central nervous system), liver, kidney, lung, and in endocrine, immune, and reproductive tissues, and are overexpressed in several tumor cell lines (Vilner et al Cancer Res. 1995, 55, 408-413.). A recent review recites several potential applications for
10 compounds having affinity for sigma receptors. Moreover, preliminary studies indicate that certain sigma agonists or sigma antagonists may be suitable for imaging or treating various cancers. See, for example, Wayne Bowen and Fabian Moebius (Pharm. Acta Helv. 2000, 74, 211-218; Trends Pharmacol. Sci. 1997, 18,67-70.).

15 Similar to the serotonin receptors, the sigma receptors (including sigma-1 and sigma-2) that are normally expressed in the brain are also over expressed in a number of tumors. Sigma receptors, originally thought be a subclass of opiate receptors, are nondopaminergic, nonopiate membrane proteins that possess high affinity for haloperidol and various other neuroleptics. Two subtypes, termed σ -1 and σ -2 have now been identified.

20 The (+)-benzomorphans ((+)-[³H]-pentazocine) selectively label the σ -1 sites; the enantiomeric (-)-benzomorphans show lower affinity and no differentiation between the two sites. The σ -2 sites, however are identified with [³H]-DTG a nonselective s-1/s-2 ligand in the presence of dextralophan, which masks binding of the σ -1 sites (Pharmacological reviews
25 vol 42(4), 355-402, 1990).

Several studies have now been reported on the overexpression of sigma receptors in human and murine tumors including human melanoma, small cell lung carcinoma, human breast carcinomas and both androgen-dependent and -independent prostate carcinomas
30 (Cancer Research vol 55(2), 408-413, 1995; Bioconjugate Chem 1997;8:304-9; and Nucl Med Biol 1998;25:189-94). See also John (U.S. Patent 5,919, 934), Nuclear medicine Biology vol 28, 657-666 2001, and international publications to Mach (WO/0180905 A2 and WO 00/71171 A2).

Adrenoreceptors, including α_1 receptors, are another family of G-protein-coupled receptors expressed in the brain, and are expressed in prostatic diseases such as benign prostatic hyperplasia (BPH) and are used for the treatment of this disease (Journal of
5 Andrology vol 12, 389-394, 1991 and Jour. Medicinal Chem. Vol 40, 1293-1315, 1997).

The wide spread availability of ^{99m}Tc in most major hospitals and the routine use and practicality of SPECT imaging in nuclear medicine gives impetus to the development of such receptor-imaging agents labeled with technetium-99m. The use therapeutic rhenium-186 or
10 rhenium-188 may permit the radiotherapy of diseases to which these small receptor-specific complexes bind.

The most widely used isotope in clinical nuclear medicine, technetium-99m, possesses ideal characteristics ($t_{1/2} = 6.02$ h, 140 keV monoenergetic γ -emission) for nuclear medicine
15 imaging and is available on demand from a ^{99}Mo - ^{99m}Tc generator system.


Thus, new and useful radiolabeled diagnostic agents, including ^{99m}Tc and ^{186}Re and ^{188}Re labeled diagnostic agents, for imaging tissues, particularly tissues expressing or over
expressing one or more of the receptors discussed *supra*, would be desirable. Moreover ^{99m}Tc
20 and ^{186}Re and ^{188}Re labeled diagnostic and therapeutic agents suitable for use in imaging or treating melanoma, prostate cancer, other tumor or diseased states, various portions of the brain or other tissues expressing or overexpressing one or more receptors discussed *supra* would be desirable.

25 SUMMARY OF THE INVENTION

The present invention provides new radiolabeled diagnostic and therapeutic agents which comprise a metal or radiometal center. Preferred radiometals include 99m-technetium and one or more radioactive and non-radioactive isotopes of rhenium. Preferred agents are useful for *in-vivo* and *in-vitro* imaging of tumors, such as neoplasms, carcinoma and
30 melanoma, or tissues or organs expressing one or more proteins, receptors or neuroreceptors, such as serotonin receptors, α receptors, σ receptors, calcium channel receptors or emopamil binding proteins adrenergic receptors, adrenoceptors receptors, dopamine receptors, and any subclass of receptors or proteins thereof. Particularly preferred agents are useful for *in-vivo*

and *in-vitro* imaging. Preferred agents of the present invention comprise an oxotechnetium core (Tc=O) or an oxorhenium core (Re=O) linked to a tertiary amine pharmacophore such as, but not limited to, a *N*-substituted piperidine pharmacophore.

5 Thus, compounds provided by the invention include those according to Formula I:



wherein

A is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted heteroaralkyl, optionally substituted heteroaryl, and -X-Y;

B is independently selected at each occurrence of B from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, , optionally substituted alkoxy, halogen, hydroxy, optionally substituted alkoxyalkyl, optionally substituted amino, optionally substituted mono and dialkyl amino, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted heteroaralkyl, optionally substituted heteroaryl, and -X-Y, wherein at least on occurrence of B is not hydrogen;

20 X is a linking group comprising a backbone chain having 1 to about 8 atoms, the backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain ;

k is an integer from about 1 to about 3; and

Y is a group capable of chelating to at least one metal ion,

25 wherein at least one of A or B is chosen to be -X-Y.

Preferred compounds of Formula I provided by the present invention include those compounds having one B group, e.g., $k = 1$, attached at the 2, 3, or 4 position of the piperidine ring. Other preferred compounds of Formula I provided by the present invention have two B groups, e.g., $k = 2$, where both B groups are attached together or independently at the two (*ortho*), three (*meta*) or four (*para*) position of the piperidine ring.

Other compounds provided by the invention include those according to Formula II:



where Y is a chelating ligand capable of binding a metal ion, X is a linking group containing
 5 a backbone chain having 1 to about 8 atoms, and R₁ and R₂ each are independently selected
 unsubstituted alkyl groups having from 1 to about 8 carbon atoms and substituted alkyl
 groups having from 1 to about 8 carbon atoms which are substituted with one or more groups
 selected from optionally substituted aryl, preferably having from 6 to 12 carbon atoms,
 optionally substituted aralkyl, preferably having from 7 to 18 carbon atoms, optionally
 10 substituted cycloalkyl, preferably having from 3 to 8 carbon atoms, optionally substituted
 heteroalicyclic, preferably having from 3 to 8 carbon atoms and between 1 and 3 heteroatoms
 in the heteroalicyclic ring, optionally substituted heteroaralkyl, preferably having from 7 to 18
 carbon atoms and between 1 and 3 heteroatoms in the heteroaryl ring, optionally substituted
 heteroaryl, preferably having from 7 to 18 carbon atoms and between 1 and 3 heteroatoms in
 15 the heteroaryl ring, wherein at least one of R₁ or R₂ is a substituted alkyl group.

Preferred compounds of Formula II include those compounds in which X is a C₂₋₈-
 alkylene, R₁ is an optionally substituted C₁₋₆alkyl group and R₂ is an optionally substituted
 (aryl)C₁₋₄alkyl group or an optionally substituted (heteroaryl)C₁₋₄alkyl group.

20

Preferred linking groups, X, are lower alkyl groups having from 1 to about 8 atoms in
 the backbone such as, e.g., -(CH₂)_n-, ether groups having 1 to 8 atoms in the backbone such
 as, e.g., -(CH₂)_n-O-(CH₂)_m-, ester groups having 1 to 8 atoms in the backbone such as, e.g., -
 (CH₂)_n-CO-O-(CH₂)_m-, thioether groups having 1 to 8 atoms in the backbone such as, e.g., -
 25 (CH₂)_n-S-(CH₂)_m-, and amido groups having 3-8 atoms in the backbone such as, e.g., -
 (CH₂)_nCO-NH-CH₂CH₂- or -(CH₂)_nCO-NH-, where n and m are non-negative integers and
 the sum n+m is typically between about 1 and about 8. Particularly preferred linking groups
 X have between about 2 and about 5 atoms in the backbone.

30 Linking groups X may optionally have one or more substituents attached to the
 backbone chain including pendant aromatic groups. Preferred substituents include alkyl
 groups having from 1 to about 6 carbon atoms and from 0 to about 3 oxygen, sulfur, or
 oxidized sulfur atoms, hydroxyl, amino, carboxyl, alkoxy groups having from 1 to about 6

carbon atoms, aminoalkyl groups having from 1 to about 6 carbon atoms, dialkylaminoalkyl groups where each alkyl group has from about 1 to about 6 carbon atoms, halogen atoms including F, Cl, Br, and I, aromatic groups having about 5 to about 18 ring atoms which may include 0, 1, 2, or 3 N, O or S ring atoms.

5

The compounds of the invention are then complexed with a metal ion using methods well known in the art to provide metal complexes. Imaging applications typically comprise metal complexes which are radiolabelled and more typically comprise at least one radiolabelled metal ion (e.g., a radioactive metal ion). Therapeutic applications typically
10 comprise metal complexes of the invention which are cytotoxic and may comprise cold (e.g., non-radioactive metal ions) or radiolabelled metal ions or a combination thereof. Typical radiolabeled complexes of the invention are cationic or neutral. Preferred radiometal ions include isotopes of metal ions that emit α , β^- , β^+ or γ radiation, including metal ions selected from the group consisting of technetium, rhenium, yttrium, copper, gallium, indium,
15 bismuth, platinum and rhodium. Particularly preferred radiolabeled complexes of the invention comprise a technetium or rhenium metal ion.

The present invention further provides methods for *in-vivo* or *in-vitro* imaging of at least one tissue expressing one or more protein or receptor for which radiolabeled complexes
20 have affinity, the method comprising the steps of

providing a radiolabeled complex comprising a metal ion and a compound according to Formula I, Formula II or any subformula thereof;

contacting the tumor(s) with the radiolabeled complex; and

making a radiographic image to image the tissue(s).

25

Preferred tissues suitable for use in the imaging methods of the present invention are not particularly limited. However, typically preferred tissues include those tissue which express or over-express one or more proteins, receptors or neuroreceptors, such as serotonin receptors, α receptors, σ receptors, calcium channel receptors or emopamil binding proteins
30 adrenergic receptors, adrenoceptors receptors, dopamine receptors, and any subclass of receptors or proteins thereof. Preferred tissues which can be imaged by the methods of the invention include brain tissue, organs, tumors and cells or tissues and the like which express such proteins and/or receptors.

The present invention also provides methods for *in-vivo* or *in-vitro* imaging of at least one tumor comprising the steps of:

- providing a radiolabeled complex comprising a metal ion and a compound according
- 5 to Formula I, Formula II or any subformula thereof;
- contacting the tumor(s) with the radiolabeled complex; and
- making a radiographic image to image and/or visualize the tumor(s).

In preferred embodiments, the radiolabeled complexes are injected into a mammal to
10 obtain an image of at least one tissue, organ, or tumor. Preferable radiolabeled complexes accumulate in the tissue, organ, or tumor. Images are obtained by conventional techniques such as use of a radioscintillation camera such as those used for positron emission tomography (PET), single photon emission tomography (SPECT) or the like.

15 The present invention also provides methods for the treatment of cancer or disease comprising the steps of:

- providing a cytotoxic metal complex comprising a metal ion and a compound
- according to Formula I or II or any subformula thereof; and
- contacting the tumor(s) or tissue(s) with the cytotoxic metal complex.

20

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a plot of σ_1 binding affinity for various Re complexes of the invention compared to [^3H]-Pentazocine;

25

FIG. 2 is a plot of σ_2 binding affinity for various Re complexes of the invention compared to [^3H]-DTG];

FIG. 3 is a plot of α_1 binding affinity of various Re complexes of the invention compared to
30 [^3H]-prazosin;

FIG. 4 is a plot of 5HT_{1A} binding affinity of various Re complexes of the invention compared to [^3H]-8-OH-DAPT];

FIG. 5 is an ORTEP representation of complex Re-24 determined by X-ray crystallography;

FIG. 6 is a plot of σ_1 binding affinity for various Re complexes of the invention compared to
5 $[^3\text{H}]$ -Pentazocine;

FIG. 7 is a plot of σ_2 binding affinity for various Re complexes of the invention compared to
 $[^3\text{H}]$ -DTG];

10 FIG. 8 is a plot of α_1 binding affinity of various Re complexes of the invention compared to
 $[^3\text{H}]$ -prazosin;

FIG. 9 is a plot of 5HT_{1A} binding affinity of various Re complexes of the invention compared
to $[3\text{H-8-OH-DAPT}]$;

15

FIG. 10 is a plot of σ_1 binding affinity for various Re complexes of the invention compared to
 $[^3\text{H}]$ -Pentazocine;

FIG. 11 is a plot of σ_2 binding affinity for various Re complexes of the invention compared to
20 $[^3\text{H}]$ -DTG];

FIG. 12 is a plot of α_1 binding affinity of various Re complexes of the invention compared to
 $[^3\text{H}]$ -prazosin; and

25 FIG. 13 is a plot of 5HT_{1A} binding affinity of various Re complexes of the invention
compared to $[3\text{H-8-OH-DAPT}]$.

DEFINITIONS

30 Tr and Trt refer to trityl groups, e.g., triphenylmethyl groups.

DTG refers to ditolyl guanidine.

AADT refers to amino-amido-dithiolate ligands, preferred AADT ligands have a N-[2-(2-
mercapto-ethylamino)-ethylamino]-ethanethiol structure.

DADT refers to diamino-dithiolate ligands, preferred DADT ligands have a 2-[2-(2-mercapto-ethylamino)-ethylamino]-ethanethiol structure.

The term "substituted", as used herein, means that any one or more hydrogens on the
5 designated atom is replaced with a group selected from the defined list, provided that the designated atom's normal valence is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =O), then 2 hydrogens on the atom are replaced. Keto substituents are not directly attached to aromatic ring atoms.

10 When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R^{*}, then said group may optionally be substituted with up to two R^{*} groups and R^{*} at each occurrence is selected independently from the definition of R^{*}. Also, combinations of substituents and/or
15 variables are permissible provided that such combinations result in stable compounds.

As indicated herein, various substituents of the compounds of the present invention and various formulae set forth herein are "optionally substituted", including, e.g., a linker or carboxylate leaving group. When substituted, those substituents can be substituted at one or
20 more of any of the available positions, typically 1, 2, 3, 4, or 5 positions, by one or more suitable groups such as those disclosed herein.

Suitable groups or "substituted" moieties for hydrogen atoms in compounds of the invention include, e.g., halogen such as fluoro, chloro, bromo or iodo; cyano; hydroxyl; nitro;
25 azido; alkanoyl, such as a C₁₋₆ alkanoyl group such as acyl and the like; carboxamido; alkyl groups including those groups having 1 to about 12 carbon atoms, preferably 1 - 6 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 12 carbon atoms, preferably 2 - 6 carbon atoms; alkoxy groups including those having one or more oxygen linkages and from 1 to about 12 carbon atoms, preferably 1
30 - 6 carbon atoms; aryloxy groups such as phenoxy and benzyloxy; alkylthio groups including those moieties having one or more thioether linkages and from 1 to about 12 carbon atoms, preferably 1 - 6 carbon atoms; alkylsulfinyl groups including those moieties having one or more sulfinyl linkages and from 1 to about 12 carbon atoms, preferably 1 - 6 carbon atoms;

alkylsulfonyl groups including those moieties having one or more sulfonyl linkages and from 1 to about 12 carbon atoms, preferably 1 - 6 carbon atoms; aminoalkyl groups such as groups having one or more N atoms and from 1 to about 12 carbon atoms, preferably 1 - 6 carbon atoms; carbocyclic aryl groups having 6 or more carbons, particularly phenyl and benzyl (e.g., wherein an Ar group can be substituted or unsubstituted biphenyl moiety); arylalkyl having 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms, with benzyl being a preferred group; arylalkoxy having 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms, with O-benzyl being a preferred group; or a heteroaromatic or heteroalicyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O or S atoms.

As used herein, "alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups, having the specified number of carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. Preferred alkyl groups are lower alkyl groups having from 1 to about 6 carbon atoms. The term C₁₋₆ alkyl as used herein means alkyl groups consisting of 1 to 6 carbon atoms, which may contain a cyclopropyl moiety.

"Cycloalkyl" is intended to include saturated ring groups, having a specified number of carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl and bridged or caged saturated ring groups such as norbornane or adamantane and the like. Preferred cycloalkyl groups are cycloalkyl groups having from 3 to about 8 ring atoms. The term C₃₋₈ cycloalkyl as used herein means cycloalkyl groups consisting of a aliphatic ring with 3 to 8 atoms in the ring.

"Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration comprising one or more unsaturated carbon-carbon bonds, which may occur in any stable point along the chain such as, e.g., ethenyl and propenyl. Preferred alkenyl groups are lower alkenyl groups having from 2 to about 6 carbon atoms. The term C₂₋₆ alkenyl as used herein means alkenyl groups consisting of 2 to 6 carbon atoms.

"Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration comprising one or more triple carbon-carbon bonds that may occur in any stable

point along the chain such as, e.g., ethynyl and propynyl. Preferred alkynyl groups are lower alkynyl groups having from 2 to about 6 carbon atoms. The term C_{2-6} alkynyl as used herein means alkynyl groups consisting of 2 to 6 carbon atoms.

5 As used herein, the term "heterocyclic group" is intended to include saturated, partially unsaturated, or unsaturated (aromatic) groups having 1 to 3 (preferably fused or spiro) rings with 3 to about 8 members per ring at least one ring containing an atom selected from N, O or S. The nitrogen and sulfur heteroatoms may optionally be oxidized. The term "heteroalicyclic" or "heterocycloalkyl" is used to refer to saturated or partially unsaturated
10 heterocyclic groups.

As used herein, the term "aryl" includes groups that contain 1 to 3 separate or fused rings and from 6 to about 18 ring atoms, without hetero atoms as ring members. Specifically preferred carbocyclic aryl groups include phenyl, and naphthyl including 1-naphthyl and 2-
15 naphthyl.

"Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example $-C_v(X^i)_{w_i}(H_{2v+1-\Sigma(w_i)})$ where $v = 1$ to 6 ; $X^i = F(i=1)$, $Cl(i=2)$, $Br(i=3)$,
20 $I(i=4)$ and $\Sigma w_i \leq 2v+1$). Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl. Preferred haloalkyl groups are lower haloalkyl groups having from 1 to about 6 carbon atoms. The term C_{1-6} haloalkyl as used herein means haloalkyl groups consisting of 1 to 6 carbon atoms.

25 As used herein, the term "hydrocarbon group" is intended to include alkyl, cycloalkyl, alkenyl, alkynyl, and aryl groups or a group that comprises a combination of two or more alkyl, cycloalkyl, alkenyl, alkynyl or aryl group regions. Hydrocarbon groups may further comprise heteroatoms such as N, O, F, Si, S, Cl, Br and the like. Preferably, hydrocarbon groups have from 0 to about 3 heteroatoms. The term lower hydrocarbon group as used
30 herein means a hydrocarbon group consisting of 1 to 6 carbon atoms which may include 1, 2, or 3 heteroatoms.

As used herein, the term "lipophilic group" refers to any hydrophobic group that is

soluble in or miscible with lipids, hydrocarbons and other hydrophobic materials. Examples of lipophilic groups include, but are not limited to, long-chain C₆-C₃₂ alkyl groups that include linear alkyls, branched alkyls with one or more branch points or linear or branched alkyls which include one or more C₃-C₈ cycloalkane groups, long-chain C₆-C₃₂ alkenyl groups with one or more C-C double bonds that include linear alkenyls, branched alkenyls with one or more branch points or linear or branched alkenyls which include one or more C₃-C₈ cycloalkane or cycloalkene groups, long-chain C₆-C₃₂ alkynyl groups with one or more C-C triple bonds that include linear alkynyls, branched alkynyls with one or more branch points or linear or branched alkynyls which include one or more C₃-C₈ cycloalkane groups or long-chain C₆-C₃₂ alkyl, alkenyl or alkynyl groups that are optionally substituted with aryl, halogen, alkoxy, mono- or di(C₁-C₆)amino, C₁-C₆-alkyl ester.

Suitable aralkyl groups of compounds of the invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups. Typical aralkyl groups contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms. Preferred aralkyl groups include benzyl and methylenenaphthyl (-CH₂-naphthyl), 1-phenethyl, 2-phenethyl, ω-phenyl-C₁₋₈alkyl, and other carbocyclic aralkyl groups, as discussed above.

"Alkoxy" means an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy. Preferred alkoxy groups are lower alkoxy groups having from 1 to about 6 carbon atoms.

The term "halogen" means fluorine, chlorine, bromine, iodine, or astatine.

As used herein, the term "metal ion" is intended to include any metal ion including all natural and synthetic isotopes thereof and further includes both radioactive and non-radioactive metal ions. The term radiolabelled typically refers to compounds or complexes comprising at least one radioactive isotope. In preferred embodiments of the invention, radiolabelled typically comprises complexes and compounds having at least one metal ion which is present as one or more isotopes of which at least isotope is radioactive.


DETAILED DESCRIPTION OF THE INVENTION AND
PREFERRED EMBODIMENTS THEREOF

5 The present invention provides new radiolabeled diagnostic and therapeutic agents which comprise a metal center. Preferred diagnostic agents comprise at least one radiometal, e.g., at least one radioactive isotope. Preferred therapeutic agents may comprise a radiolabelled or cold metal ions (e.g., isotopes of a metal which are not radioactive). Preferred radiometals include ^{99m}-technetium and one or more radioactive isotopes of
10 rhenium. Preferred agents of the present invention typically comprise an oxotechnetium core (Tc=O) or an oxorhenium core (Re=O) chelated by at least one ligand group Y linked to a tertiary amine pharmacophore as described in Formula I and Formula II *supra*. Preferred radiolabeled metal complexes of the invention comprise a neutral or cationic metal complex, e.g., a metal ion and the inner coordination sphere of ligands taken together are neutral or
15 cationic. Preferably, the overall charge of the radiolabeled complex is either neutral or cationic.

 The present invention provides small-molecule metal-complexes and methods of using such small molecule metal complexes as diagnostic and therapeutic probes for the non-
20 invasive imaging and localization of proteins or receptors expressed (or over expressed) in normal tissues and organs as well as identification of said receptors over expressed in certain diseases or tumors.

 Particular proteins, receptors and neuroreceptors, such as serotonin receptors, including 5HT receptors, adrenoreceptors, including α_1 receptors, sigma receptors including σ_1 and σ_2 receptors, calcium channel receptors, emopamil binding proteins, adrenergic receptors, dopamine receptors, are implicated in various neurological disorders and are also over expressed in a variety of tumors or pathological conditions. The tetradentate N₂S₂
25 ^{99m}Tc-complexes and the corresponding rhenium complexes are linked via a linker to a tertiary amine, e.g., a substituted piperidine or a N-alkyl-N-((hetero)aryl)alkylamine, or the like, and possess affinity for 5HT_{1A}, sigma-1, sigma-2, Ca²⁺ channel receptors, EBP, or alpha-1 receptors expressed or over expressed on the cell surface or within the cell of neuronal cells or tumor cells.
30


Thus, the invention provides compounds according to the following Formula II:



where Y is a chelating ligand capable of binding metal ion, X is a linking group containing a backbone chain having 1 to about 8 atoms, and R_1 and R_2 each are independently
 5 selected unsubstituted alkyl groups having from 1 to about 8 carbon atoms alkoxyalkyl groups having from about 2 to about 8 carbon atoms, and substituted alkyl or alkoxyalkyl groups having from 1 to about 8 carbon atoms which are substituted with one or more groups selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, and optionally substituted heteroaryl, wherein at least one of R_1 or
 10 R_2 is a substituted alkyl group.

Preferred compounds of Formula II include those compounds wherein R_1 is an optionally substituted alkyl (preferably C_{1-6} alkyl), R_2 is an optionally substituted aryl or heteroaryl substituted alkyl (preferably an (aryl) C_{1-4} alkyl or (heteroaryl) C_{1-4} alkyl), and X is an optionally
 15 substituted C_{3-8} alkylene (preferably a C_{3-6} alkylene).

Particularly preferred compounds of Formula II of the present invention include those compounds of Formula II-A:



wherein:

R_A is independently chosen at each occurrence of R_A from the group consisting of hydrogen, lower alkyl having 1 to about 4 carbon atoms, alkyl ester groups having about 2 to about 8 carbon atoms, aryl ester groups having about 7 to about 18 carbon atoms, alkyl amide
 25 groups having about 2 to about 8 carbon atoms, aryl amide groups having about 7 to about 18 carbon atoms, di(alkyl)aminoalkyl groups where each alkyl group has 1 to about 4 carbon atoms, and $-XNR_1R_2$;

R_B is hydrogen or a lower alkyl group having from 1 to about 6 carbon atoms for each occurrence of R_B ; or

$-(CR_A R_B)-$ taken in combination is $-(C=O)-$ such that there are zero or one $-(C=O)-$ groups;

R_C is independently selected at each occurrence of R_C from the group consisting of hydrogen, lower alkyl groups having 1 to about 8 carbon atoms, alkoxyalkyl group having
 5 from 2 to about 8 carbon atoms, alkyl ester or aryl ester groups having about 2 to about 8 carbon atoms, alkyl amide or aryl amide groups having about 2 to 8 carbon atoms, di(alkyl)aminoalkyl groups where each alkyl group has 1 to about 4 carbon atoms, and -
 XNR_1R_2 ;

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the
 10 backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain; and

R_1 and R_2 each are independently selected unsubstituted alkyl groups having from 1 to about 8 carbon atoms, alkoxyalkyl group having from 2 to about 8 carbon atoms, and substituted alkyl or alkoxyalkyl groups having from 1 to about 8 carbon atoms which are
 15 substituted with one or more groups selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, and optionally substituted heteroaryl, wherein at least one of R_1 or R_2 is a substituted alkyl or alkyloxy group;



n is either 2 or 3 and is independently chosen at each occurrence of n ; and


at least one occurrence of R_A or R_C in Formula I is chosen to be $-XNR_1R_2$,

20 where the metal complex resulting from the binding of the compound to the metal ion is either neutral or cationic.


Other preferred compounds of the present invention according to Formula I discussed *supra* include compounds according to Formulae I-A, I-B, I-C, and I-D:

25





I-C



I-D

Radiolabeled complexes of the present invention can be isomerically pure or can
 5 comprise a mixture of isomers including mixtures of two or more isomers selected from
 enantiomers, diastereomers, complexation isomers, rotational isomers, geometric isomers,
 tautomers and like isomers. For example, isomeric complexes which result from the relative
 orientation of metal ligand group and a substituent on the metal chelate group, Y, such as
 R_A , R_C , R, XNR_1R_2 , X-(4-B-N-piperidinyl), or X-(N-A-piperidin-4-yl) are typically referred
 10 to as *syn/anti* isomers or alternatively as *cis/trans* isomers where the *syn* isomer has the oxo
 ligand and the ligand substituent oriented in generally the same direction and the *anti* isomer
 has the oxo ligand and the ligand substituent oriented in generally opposite directions.

Preferred metal ions for use in radiolabeled complexes of the invention are sources
 15 capable of emitting one or more discrete forms of radiation. Preferred radiation emissions
 include alpha, beta and gamma radiation emissions. Additionally preferred are metal ions
 that emit alpha, beta(+), beta(-) or gamma radiation with sufficient energy to be detected by
 standard radiography techniques or have sufficient alpha, beta or gamma energy for
 radiotherapeutic applications. Particularly preferred metal ions include one or more isotopes
 20 of metals selected from technetium, rhenium, yttrium, copper, gallium, indium, bismuth,
 platinum and rhodium. Technetium-99m and radioactive isotopes of rhenium are exemplary
 metal ion for use in the present invention. Metal ions suitable for use in radiolabeled
 complexes of the invention may include additional ligands coordinated to the metal atom.
 Preferred ligands include oxo, nitride, fluoride, chloride, bromide, iodide, carbonyl, isonitrile,
 25 nitrile, nitrosyl, alkoxide groups with 1 to about 6 carbon atoms, amine groups with 1 to
 about 12 carbon atoms, water, ether groups with 2 to about 8 carbon atoms, thioether groups
 with 2 to about 8 carbon atoms including thiophene, phosphines and phosphates with 1 to
 about 20 carbon atoms and other common ligands for technetium and rhenium chemistry.
 Particularly preferred technetium and rhenium metal ions additionally comprise an oxo
 30 ligand, e.g., a $Tc=O$ or $Re=O$.

Additionally, preferred complexes of the invention have a chelating ligand moiety, Y, where the chelating ligand is able to bind to a metal ion through a plurality of donor atoms. Each donor atom is typically C, N, O, S, or P but other donor atoms are also acceptable for certain applications. Preferred donor atoms are N and S. The plurality of donor atoms can be present in a single compound or can be present in two or more compounds such that the two compounds bind to the metal to form the chelating ligand-metal complex. In certain embodiments, one compound will comprise three donor atoms and one or more additional compound will each independently comprise a single donor atom. Alternatively, two compounds, which can be the same or different, each of which can independently comprise two or more donor atoms can bind to a metal center to form a bis-ligand metal complex.

Particularly preferred compounds and radiolabeled metal complexes comprise a tetradentate ligand system wherein the tetradentate ligand is contained in a single compound that includes four donor atoms. In additional preferred compounds and radiolabeled metal complexes, the tetradentate chelating ligand is a "3+1" ligand system wherein three donor atoms of the tetradentate chelating ligand moiety Y are contained in one compound and the fourth donor atom is present in another compound. Other chelating ligands, including bidentate, pentadentate, and ligands capable of chelating to two or more metal ions, are also contemplated for use in the compounds and metal complexes provided by the present invention.


Preferred linking groups, X, are lower alkyl groups having from 1 to about 8 atoms in the backbone such as, e.g., $-(CH_2)_n-$, ether groups having 3 to 8 atoms in the backbone such as, e.g., $-(CH_2)_n-O-(CH_2)_m-$, ester groups having 4 to 8 atoms in the backbone such as, e.g., $-(CH_2)_n-CO-O-(CH_2)_m-$, thioether groups having 3 to 8 atoms in the backbone such as, e.g., $-(CH_2)_n-S-(CH_2)_m-$, and amido groups having 4-8 atoms in the backbone such as, e.g., $-(CH_2)_nCO-NH-(CH_2)_m-$ where n and m are non-negative integers and the sum $n+m$ is typically between about 2 and about 8. Particularly preferred linking groups X have between about 2 and about 5 atoms in the backbone.

Linking groups X may optionally have one or more substituents attached to the backbone chain including pendant aromatic groups. Preferred substituents include alkyl groups having from 1 to about 6 carbon atoms and from 0 to about 3 N, O or S atoms,

hydroxyl, amino, carboxyl, alkoxy groups having from 1 to about 6 carbon atoms, aminoalkyl groups having from 1 to about 6 carbon atoms, dialkylaminoalkyl groups where each alkyl group has from about 1 to about 6 carbon atoms, halogen atoms including F, Cl, Br, and I, aromatic groups having about 5 to about 18 ring atoms which may include 0, 1, 2, or 3 N, O or S ring atoms.

Radiolabeled complexes of the invention include neutral or cationic metal centers where the metal center refers to the metal ion and the inner sphere of ligands directly bound to the metal ion. Preferred radiolabeled complexes of the invention contain a metal center that is neutral or cationic. Moreover, the radiolabeled complex comprising a metal ion and a compound of the formula Y-X-NR₁R₂ taken in its entirety is neutral or cationic.

Other preferred compounds provided by the invention according to Formula I and more preferably according to Formula I-C include the following compounds comprising a chelate, Y, according to Formula III:



wherein:

R_A is independently chosen at each occurrence of R_A from the group consisting of hydrogen, lower alkyl having 1 to about 4 carbon atoms, alkyl ester groups having about 2 to about 8 carbon atoms, aryl ester groups having about 7 to about 18 carbon atoms, alkyl amide groups having about 2 to about 8 carbon atoms, aryl amide groups having about 7 to about 18 carbon atoms, di(alkyl)aminoalkyl groups where each alkyl group has 1 to about 4 carbon atoms, and -XNR₁R₂;

R_B is hydrogen or lower alkyl having from about 1 to about 6 carbon atoms for each occurrence of R_B; or

-(C R_A R_B)- taken in combination is -(C=O)- such that there are zero or one -(C=O)- groups;

R_C is selected from the group consisting of hydrogen, lower alkyl groups having 1 to about 8 carbon atoms, alkoxyalkyl group having from 2 to about 8 carbon atoms, alkyl ester


or aryl ester groups having about 2 to about 8 carbon atoms, alkyl amide or aryl amide groups having about 2 to 8 carbon atoms, di(alkyl)aminoalkyl groups where each alkyl group has 1 to about 4 carbon atoms, and $-XNR_1R_2$;

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the
 5 backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain ; and

R_1 and R_2 each are independently selected unsubstituted alkyl groups having from 1 to about 8 carbon atoms, alkoxyalkyl group having from 2 to about 8 carbon atoms, and substituted alkyl or alkoxyalkyl groups having from 1 to about 8 carbon atoms which are
 10 substituted with one or more groups selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted heteroaryl;

n is either 2 or 3 and is independently chosen at each occurrence of n .

Preferred chelating groups according to Formula III include those chelates according
 15 to Formula III-A:



III-A

wherein


R is selected from hydrogen, $COO(R_3)$, or $C(O)NH(R_3)$;

R_3 represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
 20 optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and optionally substituted cycloalkyl;

E represents an oxo group or two hydrogen atoms.

Particularly preferred X groups, e.g. linking groups between the amine pharmacophore
 25 and the metal chelate, in compounds according to any one of Formula I, I-A, I-B, I-C, I-D, II, or II-A include amide linkers of the formula, $-(CH_2)_m-C(O)NH-$ (where m is between about 0 and about 5), and α,ω -alkylene groups wherein the alkylene group has between about 1 and about 10 carbon atoms and between 0 and about 3 oxygen or sulfur atoms in the alkylene chain.

The present invention further provides compounds according to Formula IV:



IV

5 wherein:

B is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, optionally substituted alkoxy, optionally substituted alkoxyalkyl, optionally substituted amino, optionally substituted mono and dialkyl amino, halogen, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted heteroaralkyl, optionally substituted heteroaryl, and -X-Y;

R₄ is hydrogen, hydroxy, halogen, optionally substituted alkyl groups having from 1 to about 6 carbon atoms, optionally substituted alkoxy groups having from 1 to about 6 carbon atoms, or

15 R₄ and B taken in combination form an optionally substituted heterocyclic group having 5 or 12 ring atoms and one or two N, O, or S atoms and 1 or 2 fused rings;

R_A is independently chosen at each occurrence of R_A from the group consisting of hydrogen, lower alkyl having 1 to about 4 carbon atoms, alkyl ester groups having about 2 to about 8 carbon atoms, aryl ester groups having about 7 to about 18 carbon atoms, alkyl amide groups having about 2 to about 8 carbon atoms, aryl amide groups having about 7 to about 18 carbon atoms, di(alkyl)aminoalkyl groups where each alkyl group has 1 to about 4 carbon atoms, and -XNR₁R₂;

R_B is hydrogen or lower alkyl having from 1 to about 4 carbon atoms for each occurrence of R_B; or

25 -(C R_A R_B)- taken in combination is -(C=O)- such that there are zero or one -(C=O)- groups;

R_C is selected from the group consisting of hydrogen, lower alkyl groups having 1 to about 8 carbon atoms, alkoxyalkyl group having from 2 to about 8 carbon atoms, alkyl ester or aryl ester groups having about 2 to about 8 carbon atoms, alkyl amide or aryl amide groups


having about 2 to 8 carbon atoms, di(alkyl)aminoalkyl groups where each alkyl group has 1 to about 4 carbon atoms, and $-XNR_1R_2$;

Y is a group capable of chelating to at least one metal ion;

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the
 5 backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain;

R_1 and R_2 each are independently selected unsubstituted alkyl groups having from 1 to about 8 carbon atoms, alkoxyalkyl group having from 2 to about 8 carbon atoms, and substituted alkyl or alkoxyalkyl groups having from 1 to about 8 carbon atoms which are substituted with
 10 one or more groups selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, and optionally substituted heteroaryl; and
 n is either 2 or 3 and is independently chosen at each occurrence of n.

Particularly preferred compounds according to Formula IV provided by the present
 15 invention include those compounds according to Formula IV-A:



IV-A

wherein:

B is selected from the group consisting of optionally substituted alkyl, optionally
 20 substituted alkenyl, optionally substituted alkynyl, hydroxy, optionally substituted alkoxy,
 optionally substituted alkoxyalkyl, optionally substituted amino, optionally substituted mono
 and dialkyl amino, halogen, optionally substituted aryl, optionally substituted aralkyl,
 optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted
 heteroaralkyl, optionally substituted heteroaryl, and $-X-Y$;

25 Y is a group capable of chelating to at least one metal ion;

R is selected from hydrogen, $C(O)O(R_3)$, or $C(O)NH(R_3)$;


R_3 represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
 optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and
 optionally substituted cycloalkyl;

E represents an oxo group or two hydrogen atoms; and

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain.

5

The present invention further provides compounds according to Formula V:



V

wherein:

- 10 R_D is independently selected at each occurrence from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, amino, halogen, cyano, nitro, optionally substituted alkoxy, optionally substituted alkoxyalkyl, optionally substituted mono and dialkyl amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted
- 15 heteroalicyclic groups;

R_4 is hydrogen, hydroxy, halogen, optionally substituted alkyl groups having from 1 to about 6 carbon atoms, optionally substituted alkoxy groups having from 1 to about 6 carbon atoms, or

Z_1 and Z_2 are independently selected from CH, CR_D , and N;

- 20 p is selected from integers between about 0 and about 5;

q is selected from integers between about 0 and about 10;

- R_A is independently chosen at each occurrence of R_A from the group consisting of hydrogen, lower alkyl having 1 to about 4 carbon atoms, alkyl ester groups having about 2 to about 8 carbon atoms, aryl ester groups having about 7 to about 18 carbon atoms, alkyl amide
- 25 groups having about 2 to about 8 carbon atoms, aryl amide groups having about 7 to about 18 carbon atoms, di(alkyl)aminoalkyl groups where each alkyl group has 1 to about 4 carbon atoms, and $-XNR_1R_2$;

R_B is hydrogen or lower alkyl having from about 1 to about 4 carbon atoms for each occurrence of R_B ; or

$-(CR_A R_B)-$ taken in combination is $-(C=O)-$ such that there are zero or one $-(C=O)-$ groups;

R_C is selected from the group consisting of hydrogen, lower alkyl groups having 1 to about 8 carbon atoms, alkoxyalkyl groups having from 2 to 8 carbon atoms, alkyl ester or aryl ester groups having about 2 to about 8 carbon atoms, alkyl amide or aryl amide groups having about 2 to 8 carbon atoms, di(alkyl)aminoalkyl groups where each alkyl group has 1 to about 4 carbon atoms, and $-XNR_1R_2$;


Y is a group capable of chelating to at least one metal ion;

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain ;

R_1 and R_2 each are independently selected unsubstituted alkyl groups having from 1 to about 8 carbon atoms, alkoxyalkyl group having from 2 to about 8 carbon atoms, and substituted alkyl or alkoxyalkyl groups having from 1 to about 8 carbon atoms which are substituted with one or more groups selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, and optionally substituted heteroaryl; and

n is either 2 or 3 and is independently chosen at each occurrence of n.

Particularly preferred compounds according to Formula V provided by the present invention include those compounds according to Formula V-A:



wherein:

R_D is independently selected at each occurrence from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, amino, halogen, cyano, nitro, optionally substituted alkoxy, optionally substituted alkoxyalkyl, optionally substituted mono and dialkyl amino, optionally substituted aryl,

optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heteroalicyclic groups;

Z_1 and Z_2 are independently selected from CH, CR_D , and N;

p is selected from integers between about 0 and about 5;

5 q is selected from integers between about 0 and about 10;


R is selected from hydrogen, $C(O)O(R_3)$, or $C(O)NH(R_3)$;

R_3 represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and optionally substituted cycloalkyl;

10 E represents an oxo group or two hydrogen atoms; and

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain.

15 The present invention further provides compounds according to Formula VI:



VI

wherein:

A is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted heteroaralkyl, optionally substituted heteroaryl, and $-X-Y$;

R_A is independently chosen at each occurrence of R_A from the group consisting of hydrogen, lower alkyl having 1 to about 4 carbon atoms, alkyl ester groups having about 2 to about 8 carbon atoms, aryl ester groups having about 7 to about 18 carbon atoms, alkyl amide groups having about 2 to about 8 carbon atoms, aryl amide groups having about 7 to about 18 carbon atoms, di(alkyl)aminoalkyl groups where each alkyl group has 1 to about 4 carbon atoms, and $-XNR_1R_2$;

R_B is hydrogen or lower alkyl having from about 1 to about 4 carbon atoms for each occurrence of R_B ; or

$-(CR_A R_B)-$ taken in combination is $-(C=O)-$ such that there are zero or one $-(C=O)-$ groups;

R_C is selected from the group consisting of hydrogen, lower alkyl groups having 1 to about 8 carbon atoms, alkoxyalkyl groups having from 2 to 8 carbon atoms, alkyl ester or aryl ester groups having about 2 to about 8 carbon atoms, alkyl amide or aryl amide groups having about 2 to 8 carbon atoms, di(alkyl)aminoalkyl groups where each alkyl group has 1 to about 4 carbon atoms, and $-XNR_1R_2$;


Y is a group capable of chelating to at least one metal ion;

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain ;

R_1 and R_2 each are independently selected unsubstituted alkyl groups having from 1 to about 8 carbon atoms, alkoxyalkyl group having from 2 to about 8 carbon atoms, and substituted alkyl or alkoxyalkyl groups having from 1 to about 8 carbon atoms which are substituted with one or more groups selected from optionally substituted aryl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, and optionally substituted heteroaryl; and

n is either 2 or 3 and is independently chosen at each occurrence of n.

Particularly preferred compounds according to Formula VI provided by the present invention include those compounds according to Formula VI-A:



VI-A

wherein:

A is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted heteroaralkyl, optionally substituted heteroaryl, and $-X-Y$;

R is selected from hydrogen, $C(O)O(R_3)$, or $C(O)NH(R_3)$;

R₃ represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and optionally substituted cycloalkyl;

E represents an oxo group or two hydrogen atoms; and


5 X is a linking group comprising a backbone chain having 1 to about 8 atoms, the backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain.

In another embodiment, the present invention provides complexes wherein the metal
10 complex is neutral or cationic that include a compound according to any one of Formula I, II, IV, V, VI or any subformula thereof and a metal ion. Additional preferred complexes comprise a metal ion and a compound of any of Formulas I, II, IV, V, VI, or any subformula thereof wherein the metal ion may comprise one or more radiolabeled isotopes or non-

15 radiolabeled isotopes of the metal ion of the complex.

Preferred metal ions for use in radiolabeled complexes of the invention are sources of capable of emitting one or more discrete forms of radiation. Preferred radiation emissions include alpha, beta(+), beta(-), and gamma radiation emissions. Additionally preferred are metal ions that emit alpha, beta(+), beta(-), or gamma radiation with sufficient energy to be
20 detected by standard radiography techniques or have sufficient alpha, beta(+), beta(-), or gamma energy for radiotherapeutic applications. Particularly preferred metal ions include one or more isotopes of metals selected from technetium, rhenium, yttrium, copper, gallium, indium, bismuth, platinum and rhodium. Technetium-99m and radioactive isotopes of rhenium, e.g., ¹⁸⁶Re and/or ¹⁸⁸Re, are exemplary radiolabeled metal ions for use in the
25 radiolabeled complexes and imaging methods using same provided by the present invention.

The present invention provides radiolabeled complexes comprising a compound according to Formula II or II-A and a metal ion. Particularly preferred complexes include complexes comprising a Tc or Re ion and a compound according to Formula II or II-A having
30 a chelate Y according to Formula III-A and include those radiolabeled metal complexes according to Formula VII:



VII

wherein

M is one or more isotopes of technetium or rhenium;

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the
 5 backbone chain can optionally include ester, amide, ether or thioether linkages in the
 backbone chain; and

R₁ and R₂ each are independently selected unsubstituted alkyl groups having from 1 to
 about 8 carbon atoms, alkoxyalkyl group having from 2 to about 8 carbon atoms, and
 substituted alkyl or alkoxyalkyl groups having from 1 to about 8 carbon atoms which are
 10 substituted with one or more groups selected from optionally substituted aryl, optionally
 substituted cycloalkyl, optionally substituted heteroalicyclic, and optionally substituted
 heteroaryl, wherein at least one of R₁ or R₂ is a substituted alkyl or alkyloxy group;


R is selected from hydrogen, C(O)O(R₃), or C(O)NH(R₃);

R₃ represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl,
 15 optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and
 optionally substituted cycloalkyl; and

E represents an oxo group or two hydrogen atoms.

Preferred complexes of Formula VII include those compounds wherein R₁ is an
 20 optionally substituted alkyl (preferably C₁₋₆alkyl), R₂ is an optionally substituted aryl or
 heteroaryl substituted alkyl (preferably an (aryl)C₁₋₄alkyl or (heteroaryl)C₁₋₄alkyl), and X is an
 optionally substituted C₃₋₈alkylene (preferably a C₃₋₆alkylene).

The present invention additionally provides complexes comprising a compound
 25 according to Formula I and a metal ion. Preferred complexes include complexes comprising
 a compound according to Formula I-A, I-B or I-C having a chelate Y according to Formula
 III-A and a metal ion which may be radiolabeled or non-radiolabeled. Preferred radiolabeled
 complexes include those complexes comprising a compound according to Formula IV or IV-
 A and a metal ion, such as those metal complexes according to Formula VIII:



VIII

wherein

M is one or more isotopes of technetium or rhenium;

5 B is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, optionally substituted alkoxy, optionally substituted alkoxyalkyl, optionally substituted amino, optionally substituted mono and dialkyl amino, halogen, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted
10 heteroaralkyl, optionally substituted heteroaryl, and -X-Y;

R₄ is hydrogen, hydroxy, halogen, optionally substituted alkyl groups having from 1 to about 6 carbon atoms, optionally substituted alkoxy groups having from 1 to about 6 carbon atoms, or

15 R₄ and B taken in combination form an optionally substituted heterocyclic group having 5 or 12 ring atoms and one or two N, O, or S atoms and 1 or 2 fused rings;

Y is a group capable of chelating to at least one metal ion;

R is selected from hydrogen, C(O)O(R₃), or C(O)NH(R₃);


20 R₃ represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and optionally substituted cycloalkyl;

E represents an oxo group or two hydrogen atoms; and

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain.

25

Other preferred metal complexes comprise a compound according to Formula V or V-A and a metal ion such as those metal complexes according to Formula IX:



wherein:

M is one or more isotopes of technetium or rhenium;

R_D is independently selected at each occurrence from the group consisting of

5 optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, amino, halogen, cyano, nitro, optionally substituted alkoxy, optionally substituted alkoxyalkyl, optionally substituted mono and dialkyl amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heteroalicyclic groups;

10 R₄ is hydrogen, hydroxy, halogen, optionally substituted alkyl groups having from 1 to about 6 carbon atoms, optionally substituted alkoxy groups having from 1 to about 6 carbon atoms;

Z_1 and Z_2 are independently selected from CH, CR_D, and N;

p is selected from integers between about 0 and about 5;

15 q is selected from integers between about 0 and about 10;


R is selected from hydrogen, C(O)O(R₃), or C(O)NH(R₃);

R₃ represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and optionally substituted cycloalkyl;

20 E represents an oxo group or two hydrogen atoms; and

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain .

25 Other preferred metal complexes comprise a compound according to Formula VI or VI-A and a metal ion such as those metal complexes according to Formula X:



wherein:

M is one or more isotopes of technetium or rhenium;

A is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted heteroaralkyl, optionally substituted heteroaryl, and -X-Y;


R is selected from hydrogen, C(O)O(R₃), or C(O)NH(R₃);

R₃ represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and optionally substituted cycloalkyl;


E represents an oxo group or two hydrogen atoms; and

X is a linking group comprising a backbone chain having 1 to about 8 atoms, the backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain.

Particularly preferred radiolabeled complexes and non-radiolabelled complexes of the present invention include complexes having a Tc or Re ion and a compound selected from:




2-[[[(1-Benzyl-piperidin-4-ylcarbamoyl)-methyl]-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide;




N-(1-Benzyl-piperidin-4-yl)-3-((2-mercapto-ethyl)-[(2-mercapto-ethylcarbamoyl)-methyl]-amino)-propionamide;

5




N-(1-Benzyl-piperidin-4-yl)-4-((2-mercapto-ethyl)-[(2-mercapto-ethylcarbamoyl)-methyl]-amino)-butyramide;




10

N-(1-Benzyl-piperidin-4-yl)-2-((2-mercapto-ethyl)-[2-(2-mercapto-ethylamino)-ethyl]-amino)-acetamide;




15

N-(1-Benzyl-piperidin-4-yl)-3-[(2-mercapto-ethyl)-[2-(2-mercapto-ethylamino)-ethyl]-amino]-propionamide;




5

N-(1-Benzyl-piperidin-4-yl)-4-[(2-mercapto-ethyl)-[2-(2-mercapto-ethylamino)-ethyl]-amino]-butyramide;




10

2-[[3-(4-Benzyl-piperidin-1-yl)-propyl]-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide;




15

2-[[4-(4-Benzyl-piperidin-1-yl)-butyl]-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide;




2-[[5-(4-Benzyl-piperidin-1-yl)-pentyl]-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide;

5




2-{2-[[3-(4-Benzyl-piperidin-1-yl)-propyl]-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol;

10




2-{2-[[4-(4-Benzyl-piperidin-1-yl)-butyl]-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol;


15



2-{2-[[5-(4-Benzyl-piperidin-1-yl)-pentyl]-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol;




N-(2-Mercapto-ethyl)-2-[(2-mercapto-ethyl)-[3-(4-phenyl-piperidin-1-yl)-propyl]-amino]-acetamide;




5

N-(2-Mercapto-ethyl)-2-[(2-mercapto-ethyl)-[4-(4-phenyl-piperidin-1-yl)-butyl]-amino]-acetamide;




10

N-(2-Mercapto-ethyl)-2-[(2-mercapto-ethyl)-[5-(4-phenyl-piperidin-1-yl)-pentyl]-amino]-acetamide;




15

2-(2-((2-Mercapto-ethyl)-[3-(4-phenyl-piperidin-1-yl)-propyl]-amino)-ethylamino)-ethanethiol;




5

2-(2-((2-Mercapto-ethyl)-[4-(4-phenyl-piperidin-1-yl)-butyl]-amino)-ethylamino)-ethanethiol;




10

2-(2-((2-Mercapto-ethyl)-[5-(4-phenyl-piperidin-1-yl)-pentyl]-amino)-ethylamino)-ethanethiol;




15

N-(2-Mercapto-ethyl)-2-((2-mercapto-ethyl)-{3-[4-(2-methoxy-phenyl)-piperidin-1-yl]-propyl}-amino)-acetamide;




N-(2-Mercapto-ethyl)-2-((2-mercapto-ethyl)-{4-[4-(2-methoxy-phenyl)-piperidin-1-yl]-butyl}-amino)-acetamide;

5




N-(2-Mercapto-ethyl)-2-((2-mercapto-ethyl)-{5-[4-(2-methoxy-phenyl)-piperidin-1-yl]-pentyl}-amino)-acetamide;

10




2-[2-((2-Mercapto-ethyl)-{3-[4-(2-methoxy-phenyl)-piperidin-1-yl]-propyl}-amino)-ethylamino]-ethanethiol;


15




2-[2-((2-Mercapto-ethyl)-{4-[4-(2-methoxy-phenyl)-piperidin-1-yl]-butyl}-amino)-ethylamino]-ethanethiol;




2-[2-((2-Mercapto-ethyl)-{5-[4-(2-methoxy-phenyl)-piperidin-1-yl]-pentyl}-amino)-ethylamino]-ethanethiol;




5 2-[{3-[4-(4-Chloro-phenyl)-piperidin-1-yl]-propyl}-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide




10 2-[{4-[4-(4-Chloro-phenyl)-piperidin-1-yl]-butyl}-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide;




15 2-[{5-[4-(4-Chloro-phenyl)-piperidin-1-yl]-pentyl}-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide;




2-{2-[{3-[4-(4-Chloro-phenyl)-piperidin-1-yl]-propyl}-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol;




5 2-{2-[{4-[4-(4-Chloro-phenyl)-piperidin-1-yl]-butyl}-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol;




10 2-{2-[{5-[4-(4-Chloro-phenyl)-piperidin-1-yl]-pentyl}-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol;



15 2-[{3-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-propyl}-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide




2-[{4-[4-(4-Chloro-phenyl) -4-hydroxy -piperidin-1-yl]-butyl}-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide;




5

2-[{5-[4-(4-Chloro-phenyl) -4-hydroxy -piperidin-1-yl]-pentyl}-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide;




10


2-{2-[{3-[4-(4-Chloro-phenyl) -4-hydroxy -piperidin-1-yl]-propyl}-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol;




15 2-{2-[{4-[4-(4-Chloro-phenyl) -4-hydroxy -piperidin-1-yl]-butyl}-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol;




2-{2-[{5-[4-(4-Chloro-phenyl) -4-hydroxy -piperidin-1-yl]-pentyl}-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol;




2-{2-[[3-(Benzyl-methyl-amino)-propyl]-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol




2-[[3-(Benzyl-methyl-amino)-propyl]-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide



5 2-(2-[(2-Mercapto-ethyl)-[3-(methyl-phenethyl-amino)-propyl]-amino]-ethylamino)-ethanethiol




N-(2-Mercapto-ethyl)-2-[(2-mercapto-ethyl)-[3-(methyl-phenethyl-amino)-propyl]-amino]-acetamide




2-[[4-(Benzyl-methyl-amino)-butyl]-(2-mercapto-ethyl)-amino]-N-(2-mercapto-ethyl)-acetamide


5





2-{2-[[4-(Benzyl-methyl-amino)-butyl]-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol




N-(2-Mercapto-ethyl)-2-[(2-mercapto-ethyl)-[4-(methyl-phenethyl-amino)-butyl]-amino]-acetamide




2-(2-[(2-Mercapto-ethyl)-[4-(methyl-phenethyl-amino)-butyl]-amino]-ethylamino)-ethanethio

2-[[5-(Benzyl-methyl-amino)-pentyl]-(2-mercapto-ethyl)-amino]- *N*-(2-mercapto-ethyl)-acetamide

2-{2-[[5-(Benzyl-methyl-amino)-pentyl]-(2-mercapto-ethyl)-amino]-ethylamino}-ethanethiol

*N*-(2-Mercapto-ethyl)-2-{(2-mercapto-ethyl)-[5-(methyl-phenethyl-amino)-pentyl]-amino}-acetamide

5



2-{2-[(2-Mercapto-ethyl)-[5-(methyl-phenethyl-amino)-pentyl]-amino]-ethylamino}-ethanethiol

Tumors suitable for imaging by the method of the present invention include

10 neoplasms, carcinomas and other cancerous tumors. Preferred tumors for imaging include neoplasms of breast, prostate, lung, pancreas, liver, colon, lymphomas, gliomas, melanomas, and other neoplasms. Tumors, especially neoplasm and melanoma tumors, can be imaged *in-*

vivo or *in-vitro* in any tissue. Preferably the tumor to be imaged is in a mammalian tissue, more preferably the tumor is in a human tissue. Preferred tissues and organs include skin, heart, brain, lung, spleen, colon, liver, kidney, muscle, lymph nodes, and other internal organs.

5

In theory any tissue, organ, tumor, growth of cells, bone, or other biomaterial may be imaged using the compounds, complexes or methods of the present invention provided that the radiolabeled metal complex used in the imaging methods is selectively taken up in the target tissue such that there is sufficient contrast between the tissue, organ, tumor, growth of
10 cells, bone, or other biomaterial to be imaged and the background. Preferred tissue, organ, tumor, growth of cells, bone, or other biomaterial which are suitable for imaging using the compounds, metal complexes and imaging methods of the present invention express or overexpress one or more receptors for which the compound or metal complex has an affinity.

15

Tissues suitable for imaging using the compounds and metal complexes or the methods of the invention are not particularly limited. Preferred tissues are capable of binding or taking up compounds of the present invention or are capable of retaining the compounds of the present invention to a greater extent than other tissues in the general vicinity of the tissue to be imaged. Thus, the emission of the radiolabeled complex retained in the tissue to be
20 imaged has sufficient contrast against the other proximate tissues to allow for imaging of the tissue. Typically preferred tissues have one or more proteins and/or receptors to which the compounds of the present invention bind include one or more proteins, receptors or neuroreceptors, such as serotonin receptors, including 5HT receptors, adrenoreceptors, including α_1 receptors, sigma receptors including σ_1 and σ_2 receptors, calcium channel
25 receptors, emopamil binding proteins, adrenergic receptors, dopamine receptor subtypes and subclasses thereof and the like. More preferably, tissues comprise one or more receptors chosen from 5HT, including 5HT_{1A}, σ_1 , σ_2 , α_1 , EBP, Ca²⁺ channel receptors, and the like.

30

The present invention provides preferred methods of imaging tumors *in-vivo* or *in-vitro*, the method comprising the steps of:

providing a radiolabeled complex comprising a compound of any one of Formula I, II, IV, V, VI or any subformula thereof and a metal ion or a radiolabeled metal complex of any one of Formula VIII, IX, X or any subformula thereof;

contacting the tumor(s) with the radiolabeled metal complex; and
making a radiographic image to image the tumor(s).

Particularly preferred tumor imaging methods provided by the present invention
5 include those methods in which the radiolabeled complex comprises a metal ion and a
compound of any one of claims Formula IV-A, V-A, or VI-A.

The present invention also provides preferred methods of imaging tissues or organs,
particularly imaging of at least one tissue or organ expressing one or more receptors for which
10 radiolabeled complexes have affinity, *in-vivo or in-vitro*, the method comprising the steps of:
providing a radiolabeled complex comprising a compound of any one of Formula I, II,
IV, V, VI or any subformula thereof and a metal ion or a radiolabeled metal complex of any
one of Formula VIII, IX, X or any subformula thereof;
contacting the tissue(s) or organ(s) expressing or overexpressing receptors with the
15 radiolabeled metal complex; and
making a radiographic image to image the tissue(s).

In preferred embodiments, proteins and receptors are selected from serotonin
receptors, α receptors, σ receptors, calcium channel receptors or emopamil binding proteins
20 adrenergic receptors, adrenoceptors receptors, dopamine receptors, sigma receptors and any
subclass of receptors or proteins thereof, more preferably the receptors are selected from
5HT_{1A}, σ_1 , σ_2 , α_1 , EBP, Ca²⁺ channel receptors, and the like.

In other preferred embodiments of the invention, the tissue to be imaged is part of the
25 central nervous system, particularly the brain or the spinal cord of a patient, or a tumor or
organ which expresses one or more proteins or receptors to which one of the radiolabeled
metal complexes of the invention have a binding affinity. Particularly preferred tissues
include brain tissue which expresses one or more of proteins, receptors or neuroreceptors,
particularly brain tissue expressing one or more of 5HT_{1A}, σ_1 , σ_2 , or α_1 , EBP, Ca²⁺ channel
30 receptors, and the like.

The present invention further provides methods for the treatment of cancer, the
method comprising the steps of:

providing a cytotoxic metal complex comprising a metal ion and a compound of any one of of Formula I, II, IV, V, VI or any subformula thereof or a metal complex according to any one of Formula VIII, IX, X or any subformula thereof; and
contacting the tumor(s) with the cytotoxic metal complex.

5

Preferred methods of treatment of the invention contemplate the use of both cold metal complexes, e.g., non-radiolabeled metal complexes, and radiolabeled complexes for certain cancer therapies.

10

The present invention further provides methods of inhibiting a protein, receptor or neuroreceptor comprising the steps of

providing a metal complex comprising a metal ion and a compound of any one of claims 1-22 or a metal complex according to any one of claims 23-31; and
contacting the protein, receptor or neuroreceptor with the metal complex.

15

Preferred receptors or neuroreceptors which are suitable for inhibition by metal complexes of the invention include serotonin receptors, α receptors, σ receptors, calcium channel receptors or emopamil binding proteins adrenergic receptors, adrenoceptors receptors, dopamine receptors, and any subclass of receptors or proteins thereof, or more
20 preferably include 5HT_{1A}, σ_1 , σ_2 , α_1 , EBP, Ca²⁺ channel receptors, and the like.

The imaging and therapeutic methods of the invention generally comprise administration of an effective amount of one or more compounds of the invention to a subject including a mammal, such as a primate, especially a human, in need of such imaging or
25 treatment. For imaging applications, typically a sufficient amount of a radiolabeled complex is administered to the tissue, organ, tumor, or the like to be imaged to provide for selective uptake of the radiolabeled complex into the tissue, organ or tumor to be imaged. Preferably the amount of radiolabeled complex taken up in the tissue, organ or tumor is sufficient to be imaged and/or quantified by standard radiographic techniques.

30

The treatment methods of the invention also will be useful for treatment of mammals other than humans, including for veterinary applications such as to treat horses and livestock

e.g. cattle, sheep, cows, goats, swine and the like, and pets (companion animals) such as dogs and cats.

For diagnostic or research applications, a wide variety of mammals will be suitable subjects including rodents (e.g. mice, rats, hamsters), rabbits, primates and swine such as inbred pigs and the like. Additionally, for in vitro applications, such as in vitro diagnostic and research applications, body fluids (e.g., blood, plasma, serum, cellular interstitial fluid, saliva, feces and urine) and cell and tissue samples of the above subjects will be suitable for use.

10

Compounds of the invention may be administered singularly (i.e. sole therapeutic agent of a regime) or in combination with other agents for diagnostic or therapeutic purposes which may or may not be radiolabeled to treat or prevent diseases and conditions such as undesired cell proliferation as disclosed herein. For combined diagnostic or therapeutic applications, additional agents are preferably chemotherapy agents or neurolyptic agents.

15

Pharmaceutical compositions of the invention include a compound of the invention packaged together with instructions (written) for therapeutic use of the compound, particularly to treat a subject suffering from or susceptible to tumors, e.g., cancers, such as melanoma, prostate cancer or the like. Pharmaceutical compositions of the invention may also be packaged together with instructions (written) for therapeutic use of the compound, particularly to image tissues or tumors within a subject to diagnose, identify or locate one or more tissues or tumors within the subject.

20

25 EXAMPLES

General Experimental Details:

All chemicals and reagents, obtained from commercial sources (Aldrich Chemicals, Gibco Life Technologies), were of analytical grade and were used without further purification. ^{99m}Tc -pertechnetate was obtained via a generator (DuPont). ^1H NMR spectra were obtained on a Varian XL500 MHz instrument. Mass spectra were recorded on a MicroMass LCZ electrospray LC-MS instrument. HPLC purification was performed on a Waters Millennium Chromatography System equipped with a 996 UV-VIS diode-array detector attached in series to a gamma detector consisting of a shielded photomultiplier

30

powered by a Canberra voltage amplifier and connected to a ratemeter. For the purification of all complexes, a reversed-phase C₈ column equipped with a C₁₈ guard was eluted with methanol (solvent A) and 0.005 M phosphate-buffered saline, pH 7.4, (Sigma) (solvent B) using a linear gradient from 15:85/A:B to 90:10/A:B at a 1.0 mL/min flow rate.

5

Synthesis of Ligands and technetium and rhenium complexes.

AADT(Trt)₂ chelate (1), N-3-chloropropyl-AADT (2), and AADT(Trt)₂-N-pentachlorophenylacetate (3) were synthesized as described earlier by us [Mahmood A, Kuchma MH, Freiberg E, Goldstone J, Davison A, Jones AG. Functionalized tetradentate N₂S₂ chelates and their technetium-99m and rhenium complexes: synthesis, spectroscopy and structural characterization. In: Nicolini M, Mazzi U, eds. Technetium, rhenium and other metals in chemistry and nuclear medicine 5. Padova: Servizi Grafici Editoriali, 1999:253–7.]

15 Technetium-99m-labeled complexes can be synthesized by transmetallation of technetium-99m from a prereduced ^{99m}Tc-glucoheptonate precursor (Scheme 2). Upon heating the reaction mixture at 70 °C, ligand exchange of the AADT ligand bearing the pendant tertiary amines and the ^{99m}Tc(V)-glucoheptonate precursor yielded complexes Tc- (Complexes A-D and H-M) in nearly quantitative yields within 30 min. Typical mass
20 amounts of the ^{99m}Tc-complexes preclude their physical characterization; however, since both technetium and rhenium form structurally identical AADT complexes, analogous non-radioactive rhenium complexes were synthesized (vide infra) and used as surrogates for HPLC comparisons. Identical HPLC retention times established the existence of the proposed technetium-99m species.


25

 Using a method similar to that for ^{99m}Tc-complexes, the mono-oxorhenium(V) complexes (Examples 6-10) were obtained by reduction of perrhenate(VII) with stannous chloride in the presence of sodium glucoheptonate and the deprotected chelating ligand; heating the reaction mixture at 75 °C for 1 h afforded brownish-purple solids of the rhenium
30 complexes. Upon chelation the N-substituent on the chelate may adopt a *syn* or *anti* configuration with respect to the asymmetric M=O core. The desheilding, anisotropic environment of the M=O core and the proximity of the N-substituent in the *syn* configuration to the asymmetric oxometal core results in a downfield shift of the proton resonances *syn* to

- the M=O core, thus permitting differentiation of the *syn* and *anti* diastereomers via NMR (Lever, S. Z.; Baidoo, K. E.; Mahmood, A. Structural Proof of *Syn/Anti* Isomerism in N-Alkylated Diaminedithiol (DADT) Complexes of Technetium. *Inorg. Chim. Acta* **1990**, 176, 183-184; Francesconi, L. C.; Graczyk, G.; Wehrli, S.; Shaikh, S. N.; McClinton, D.; Liu, S.;
- 5 Zubieta, J.; Kung, H. F. Synthesis and Characterization of Neutral $M^V O$ ($M = Tc, Re$) Amine-Thiol Complexes Containing a Pendant Phenylpiperidine Group. *Inorg. Chem.*, **1993**, 32, 3114--3124; O'Neil, J. P.; Wilson, S. R.; Katzenellenbogen, J. A. Preparation and Structural Characterization of Monoamine-Monoamide Bis(Thiol) Oxo Complexes of Technetium(V) and Rhenium(V). *Inorg. Chem.*, **1994**, 33, 319-323; and Pelecanou, M.;
- 10 Chrysosou, K.; Stassinopoulou, C. I. Trends in NMR Chemical Shifts and Ligand Mobility of $TcO(V)$ and $ReO(V)$ Complexes with Amino thiols. *J. Inorg. Biochem.*, **2000**, 79, 347-351).


15

REST OF THIS PAGE INTENTIONALLY LEFT BLANK




50

Scheme-II




(i) THF/MeOH/H₂O/ LiOH (ii) CH₂Cl₂, HO-C₆Cl₅, Dicyclohexylcarbodiimide (iii) CH₂Cl₂, (iPr)₂EtN (iv) TFA, Et₃SiH (v) H₂O, Na-glucosheptonate, NaMO₄, SnCl₂,

Scheme-III



Scheme - IV



Example 1: 4-Benzyl, N-(CH₂)₃-(AADT(Trt)₂)-piperidine (Ligand 15)

AADT(Trt)₂ chelate (1) (0.25 g, 0.37 mmol) was dissolved with N-(3 chloropropyl),4-benzylpiperidine (0.2 g, 0.79 mmol) in dry acetonitrile. K₂CO₃ (0.55g, 3.95 mmol) and KI (0.66g, 3.97 mmol) was added to this solution and the reaction mixture was refluxed for 30 hr under argon. The solvent was evaporated from the reaction mixture to dryness and redissolved in CH₂Cl₂ followed by filtration to remove the solids. The filtrate was evaporated and the crude pale yellow oil was chromatographed on silica with first with CH₂Cl₂ followed by 4% methanol in CH₂Cl₂ to yield a pale yellow oil (0.188 g, 0.21 mmol, 56.8 %)

¹H NMR (CDCl₃): 7.5-7.34 (m, 12H, Ar), 7.33-7.05 (m, 23H, Ar), 3.09-2.8 (q, 2H, -CH₂), 2.8-2.7 (m, 4H, -CH₂), 2.6-2.45 (d, 2H, -CH₂), 2.45-2.15 (m, 10H, -CH₂), 1.95-1.7 (t, 2H, -CH₂), 1.65-1.4 (m, 5H, -CH₂), 1.35-1.15 (m, 2H, -CH₂).

Mol.Wt: 894.28, C₅₉H₆₃N₃OS₂, C 79.2 %, H 7.1 %, N 4.7 %

Exact Mass: 893.44, ESI mass Spec (M+H)⁺ = 894.43

Example 2: 4(2-MeOphenyl)- N-(CH₂)₃-(AADT(Trt)₂)-piperidine (Ligand 16)

N-3-chloropropyl-AADT (2) (0.3 g, 0.397 mmol) was dissolved in acetonitrile along with 4-Methoxyphenyl piperidine (0.114 g, 0.595 mmol). K₂CO₃ (0.275g, 1.98 mmol) and KI (0.33g, 1.98 mmol) was added to this solution and the reaction mixture was refluxed for 30 hr under argon. The solvent was evaporated from the reaction mixture to dryness and redissolved in CH₂Cl₂ followed by filtration to remove the solids. The filtrate was evaporated and the crude pale yellow oil was chromatographed on silica with first with CH₂Cl₂ followed by 4-5% methanol in CH₂Cl₂ to yield a pale yellow oil (0.29 g, 0.318 mmol, 80.24%)

¹H NMR (CDCl₃): 7.54-7.32 (m, 12H Ar), 7.32-7.1 (m, 20H, Ar), 7.0-6.91 (d, 1H, Ar), 6.91-6.8 (d, 1H, Ar), 3.82 (s, 3H, OCH₃), 3.12-2.88 (m, 5H, -CH₂), 2.85 (s, 2H, CO-CH₂), 2.5-2.18 (10H, -CH₂), 2.1-1.9 (m, 2H, -CH₂), 1.86-1.7 (m, 2H, -CH₂), 1.64-1.5 (m, 2H, -CH₂).

Mol.Wt: 910.28, C₅₉H₆₃N₃O₂S₂, C 77.85 %, H 6.98 %, N 4.62 %

Exact Mass: 909.44, ESI mass Spec (M+H)⁺ = 910.28

Example 3: 4-Hydroxy,4-(4-Chlorophenyl)-N-(CH₂)₃-(AADT(Trt)₂)-piperidine (Ligand 18)

AADT(Trt)₂ chelate (1) (0.35 g, 0.515 mmol) was dissolved with N-(3-chloropropyl),4-hydroxy, 4-phenylpiperidine (0.223 g, 0.77 mmol) in dry acetonitrile. K₂CO₃ (0.53g, 3.85 mmol) and KI (0.255g, 1.54 mmol) was added to this solution and the reaction mixture was refluxed for 30 hr under argon. The solvent was evaporated from the reaction mixture to dryness and redissolved in CH₂Cl₂ followed by filtration to remove the solids. The filtrate was evaporated and the crude pale yellow oil was chromatographed on silica with first with CH₂Cl₂ followed by 5% methanol in CH₂Cl₂ to yield a pale yellow oil (0.279 g, 0.3 mmol, 58%)

¹H NMR (CDCl₃): 7.46-7.31 (m, 13H, Ar), 7.31-7.08 (m, 21H, Ar), 3.15-2.95 (m, 3H, -CH₂), 2.9-2.7 (m, 3H, -CH₂), 2.7-2.45 (m, 3H, -CH₂), 2.45-2.0 (m, 12H, -CH₂), 1.65-1.5 (m, 3H, -CH₂).

Mol. Wt: 930.70, C₅₈H₆₀ClN₃O₂S₂, C 74.85 %, H 6.5 %, N 4.5 %

Exact Mass: 929.38, ESI mass Spec (M+H)⁺ = 929.99

Example 4: (4-phenyl)-N-(CH₂)₃-(AADT(Trt)₂)-piperidine (Ligand 21)

N-3-chloropropyl-AADT (2) (0.35 g, 0.463 mmol) was dissolved in acetonitrile along with 4-phenyl piperidine (0.11 g, 0.682 mmol). K₂CO₃ (0.32g, 2.3 mmol) and KI (0.38g, 2.31 mmol) was added to this solution and the reaction mixture was refluxed for 30 hr under argon. The solvent was evaporated from the reaction mixture to dryness and redissolved in CH₂Cl₂ followed by filtration to remove the solids. The filtrate was evaporated and the crude pale yellow oil was chromatographed on silica with first with CH₂Cl₂ followed by 4-5% methanol in CH₂Cl₂ to yield a pale yellow oil (0.327 g, 0.372 mmol, 80.3%)

¹H NMR (CDCl₃): 7.58-7.35 (m, 13H, Ar), 7.34-7.12 (m, 22H, Ar), 3.12-2.94 (m, 4H, -CH₂), 2.88 (s, 2H), 2.6-2.2 (m, 11H, -CH₂), 2.14-1.88 (m, 2 H, -CH₂), 1.88-1.72 (m, 4 H, -CH₂), 1.72-1.5 (m, 2 H, -CH₂).

Mol. Wt: 880.26, C₅₈H₆₁N₃OS₂, C 79.14 %, H 6.98 %, N 4.77 %

Exact Mass: 879.43, ESI mass Spec (M+H)⁺ = 880.37

Example 5: N-benzyl, 4-amidocarboxy-(CH₂)-AADT(Trt)₂-piperidine (Ligand 22)

AADT(Trt)₂-N-pentachlorophenylacetate (3) (0.21 g, 0.213 mmol) was dissolved in dry CH₂Cl₂ and N-benzyl,4-aminopiperidine (0.049 g, 0.25 mmol) was added to this solution

along with diisopropylethylamine (0.033g, 0.255mmoles). The reaction was allowed to stir at room temperature for 5 hr after which the crude was reduced in volume and chromatographed on silica with 6 % methanol in CH_2Cl_2 to yield a off white solid (0.188g, 0.206 mmol, 97%)

^1H NMR (CDCl_3): 7.6-7.26 (m, 17H, Ar), 7.26-7.08 (m, 16H, Ar), 7.06-6.88 (d, 1H, Ar), 6.7-6.58 (m, 1H, Ar), 3.8-3.6 (m, 2 H, $-\text{CH}_2$), 3.45 (s, 2 H, $-\text{CH}_2$), 3.14-2.86 (m, 6 H, $-\text{CH}_2$), 2.8-2.6 (m, 2 H, $-\text{CH}_2$), 2.6-2.47 (m, 2 H, $-\text{CH}_2$), 2.46-2.35 (t, 2 H, $-\text{CH}_2$), 2.32-2.22 (m, 2 H, $-\text{CH}_2$), 2.14-1.92 (m, 2 H, $-\text{CH}_2$), 1.9-1.68 (m, 2 H, $-\text{CH}_2$), 1.54-1.3 (m, 2 H, $-\text{CH}_2$).

Mol.Wt: 909.25, $\text{C}_{58}\text{H}_{60}\text{N}_4\text{O}_2\text{S}_2$, C 76.6 %, H 6.65 %, N 6.16 %

Exact Mass: 908.42, ESI mass Spec $(\text{M}+\text{H})^+ = 909.10$

10

Example 6: Re complex of ligand 15

Ligand 15 (0.16 g, 0.179 mmol) was dissolved in 20 mL Trifluoroacetic acid and the yellow color was titrated with Et_3SiH till the solution became colorless. The deprotected ligand solution was evaporated to dryness to remove residual acid and re-dissolved in 30-40 mL degassed distilled water. To this solution was added sodium glucoheptonate (0.122 g, 0.492 mmol) and sodium perrhenate (0.067 g, 0.245 mmol) followed by adjusting the pH to 5 with NaOH. Solid SnCl_2 (0.092 g, 0.485 mmol) was then added and the solution stirred at 70 °C for 1 hr. The pH was readjusted to 5-6 and heated for an additional 2 hr at 70 °C. After allowing the solution to come to room temperature the pale purple aqueous solution was extracted with CH_2Cl_2 (15mL X 3) to yield the crude rhenium complex. Chromatography on silica with 3-4 % methanol in CH_2Cl_2 yielded the pale purple rhenium complex Re-15 (0.0855 g, 0.14 mmol, 78 %).

^1H NMR (CDCl_3): 7.38-7.18 (m, 3H, Ar), 7.18-7.08 (m, 2H, Ar), 4.663 (d, 1H), 4.565 (m, 1H), 4.18-4.05 (m, 2H), 3.96 (dd, 1H), 3.594 (ddd, 1H), 3.37 (ddd, 1H), 3.28-3.06 (m, 3H), 2.94-2.79 (m, 3H), 2.53 (d, 2H), 2.44-2.28 (m, 2H), 2.08-1.83 (m, 4H), 1.74-1.4 (m, 4H), 1.4-1.18 (m, 2H).

Mol.Wt.: 608.84, $\text{C}_{21}\text{H}_{32}\text{N}_3\text{O}_2\text{ReS}_2$, C 41.43 %, H 5.3 %, N 6.9 %

Exact Mass: 609.15, ESI mass Spec $(\text{M}+\text{H})^+ = 610.01$

Example 7: Re complex of ligand 16

The complex was synthesized using a procedure similar to that described for Re-15 using ligand-16 (0.15 g, 0.164 mmol), sodium-glucoheptonate (0.082 g, 0.33 mmol), NaReO_4 (0.045 g, 0.164 mmol) and SnCl_2 (0.062 g, 0.328 mmol). The pale purple complex was

isolated by silica chromatography by eluting with 4% Methanol in CH_2Cl_2 (0.0645 g, 0.1 mmol, 62%)

^1H NMR (CDCl_3): 7.24-7.12 (m, 2H Ar), 7.0-6.8 (m, 2H, Ar), 4.69 (d, 1H), 4.56 (m, 1H), 4.1 (d, 1H), 4.12-3.92 (m, 2H), 3.81 (s, 3H, OCH_3), 3.639 (ddd, 1H), 3.41 (ddd, 1H),
5 3.32-3.12 (m, 3H), 3.12-2.92 (m, 3H), 2.89 (ddd 1H), 2.457 (dd, 1H), 2.32-2.08 (m, 3H),
2.08-1.905 (m, 2H), 1.9-1.7 (m, 3H), 1.61 (ddd 1H).

Mol. Wt.: 624.84, $\text{C}_{21}\text{H}_{32}\text{N}_3\text{O}_3\text{ReS}_2$, C 40.37 %, H 5.16 %, N 6.72 %

Exact Mass: 625.14, ESI mass Spec ($\text{M}+\text{H}$) $^+$ = 625.86

10 Example 8: Re complex of ligand 18

The complex was synthesized using a procedure similar to that described for Re-15 using ligand-18 (0.11 g, 0.118 mmol), sodium-glucoheptonate (0.059 g, 0.237 mmol), NaReO_4 (0.0323 g, 0.118 mmol) and SnCl_2 (0.046 g, 0.242 mmol). The pale purple complex was isolated by silica chromatography by eluting with 4% Methanol in CH_2Cl_2 (0.0418 g,
15 0.065 mmol, 55%).

^1H NMR (CDCl_3): 7.455 (m, 1H, Ar), 7.42 (m, 1H, Ar), 7.345 (m, 1H, Ar), 7.303 (m, 1H, Ar), 4.683 (d, 1H), 4.577 (m, 1H), 4.2-3.9 (m, 3H), 3.657 (ddd, 1H), 3.38 (ddd, 1H), 3.3-3.08 (m, 3H), 2.94-2.68 (m, 3H), 2.64-2.38 (m, 4H), 2.24-1.88 (m, 4H), 1.84-1.66 (m, 2H),
1.66-1.5 (m, 1H)

20 Mol. Wt.: 645.25, $\text{C}_{20}\text{H}_{29}\text{ClN}_3\text{O}_3\text{ReS}_2$, C 37.23%, H 4.53 %, N 6.51 %

Exact Mass: 645.09, ESI mass Spec ($\text{M}+\text{H}$) $^+$ = 645.64.

Example 9 Re complex of ligand 21

The complex was synthesized using a procedure similar to that described for Re-15
25 using ligand-21 (0.175 g, 0.199 mmol), sodium-glucoheptonate (0.098 g, 0.395 mmol), NaReO_4 (0.081 g, 0.296 mmol) and SnCl_2 (0.15 g, 0.79 mmol). The pale purple complex was isolated by silica chromatography by eluting with 4% Methanol in CH_2Cl_2 (0.07 g, 0.117 mmol, 59.2%)

^1H NMR (CDCl_3): 7.4-7.14 (m, 5H, Ar), 4.696 (d, 1H), 4.56 (m, 1H), 4.118 (d, 1H),
30 4.1-3.9 (m, 2H), 3.64 (ddd, 1H), 3.405 (ddd, 1H), 3.32-3.1 (m, 3H), 3.1-2.94 (m, 2H), 2.6 (dd, 1H), 2.64-2.3 (m, 3H), 2.24-1.92 (m, 5H), 1.92-1.71 (m, 3H), 1.617 (ddd, 1H).

Mol. Wt.: 594.81, $\text{C}_{20}\text{H}_{30}\text{N}_3\text{O}_2\text{ReS}_2$, C 40.38 %, H 5.08 %, N 7.06 %

Exact Mass: 595.13, ESI mass Spec ($\text{M}+\text{H}$) $^+$ = 595.76.

Example 10: Re complex of ligand 22

The complex was synthesized using a procedure similar to that described for Re-15 using ligand-22 (0.10 g, 0.11 mmol), sodium-glucosaminide (0.054 g, 0.22 mmol), NaReO₄ (0.045 g, 0.165 mmol) and SnCl₂ (0.082 g, 0.43 mmol). The pale purple complex was isolated by silica chromatography by eluting with 5% Methanol in CH₂Cl₂ (0.051 g, 0.081 mmol, 74%)

¹H NMR (CDCl₃): 7.36-7.32 (m, 5H, Ar), 6.238 (d, 1H, NH), 4.955 (d, 1H), 4.692 (d, 1H), 4.7-4.52 (m, 2H), 4.26-4.08 (m, 2H), 3.92 (dd, 1H), 3.803 (m, 1H), 3.537 (s, 2H), 3.428 (ddd, 1H), 3.35-3.04 (m, 2H), 3.05-2.74 (m, 3H), 2.3-2.2 (m, 3H), 2.0-1.8 (m, 2H), 1.7-1.4 (m, 3H).

Mol. Wt.: 623.81, C₂₀H₂₉N₄O₃ReS₂, C 38.5 %, H 4.69 %, N 8.98 %

Exact Mass: 624.12, ESI mass Spec (M+H)⁺ = 624.93.

Example 11: General procedure for deprotection of trityl protected thiol groups

6.0 mg of the bis-trityl-protected AADT-ligand was dissolved in 3 ml of trifluoroacetic acid and stirred at room temperature for 5 min. 1-2 drops of triethylsilyl hydride were added until the former yellowish reaction mixture became colorless.

The solvent was evaporated completely and the residue placed under high vacuum overnight.

The synthesis of the technetium and rhenium labeled complexes is outlined in Scheme 1.

Example 12: Technetium-99m Labeling

Technetium-99m labeling was performed using 1.0 mg of the thiol-deprotected ligands (Compound A- D, F or H-M) dissolved in 0.5 ml phosphate buffer (0.005 M, pH = 7.5), which were exchange-labeled with the required activity of ^{99m}Tc-glucosaminide by heating the reaction at 60-75°C for 45 min. HPLC evaluation of the technetium-99m-labeled complexes showed 80-95% radiochemical yield.

Co-injection of the characterized rhenium complexes with the analogous technetium-99m complexes showed co-elution of the radioactive species with the corresponding UV active rhenium complex.

5 **Example 13: General procedure for rhenium complexation**

The bistrityl-protected ligand (Compound A-D, or G-M) (100 mg, 0.1 mmol) was dissolved in 0.25 ml anisol and 10 ml trifluoroacetic acid. The resulting yellow solution was stirred for 5 min and then titrated with triethylsilyl hydride until colorless. The solution was evaporated and placed on high vacuum till completely dry residue remained. The residue was
10 redissolved in 5 ml 20% MeOH in water previously argon-saturated. To this solution was added an aqueous solution of NaReO₄ (30 mg, 0.1 mmol) and Na-glucoheptonate (55 mg, 0.22 mmol) and, while stirring, solid SnCl₂ (21 mg, 0.11 mmol). The solution began to turn a brownish purple color. The pH of the reaction mixture was adjusted to 7 and the reaction was heated at 75°C for 1 hr. The solution was then cooled to room temperature and the pH was
15 adjusted to 8, followed by extraction with CH₂Cl₂. The CH₂Cl₂ extract was concentrated and chromatographed on silica gel, eluting with 4% MeOH in CH₂Cl₂ to yield the desired product as a pale purple solid.

Example 14: 5HT_{1A} Receptor Assays

20 The in vitro 5HT_{1A} binding affinities of rhenium coordinated complexes were determined in a competition assay using rat hippocampus and high-affinity 5HT_{1A}-ligand [³H]-8-OH-DPAT (135Ci/mmol, NEN Life Science Inc., Cambridge, MA). See, *Brain Res.* **1995**, 673, 217-225.

25 Male Sprague-Dawley rats (weighing 150-170 g) were sacrificed using anesthesia agent isoflurane. The brains were rapidly removed, and hippocampus, frontal cortex, hypothalamus, and striatum were hand-dissected on ice and stored at -70 °C. Tissue was thawed at room temperature and homogenized using a Brinkmann Polytron tissue disrupter in 50 volumes (wt/vol) of ice-cold 50 mM Tris-HCl buffer (pH 7.4). The suspension was
30 centrifuged twice at 27,000 g for 20 min at 4 °C. The membrane pellets were resuspended in 50 volumes of (wt/vol) Tris-HCl buffer and incubated at 37 °C for 20 min in a water bath, before a final centrifugation step (27,000 g; 20 min; 4 °C). The final tissue pellets were stored at -70 °C until assayed.

Twelve concentrations of the nonradioactive rhenium complexes ranging from 1×10^{-11} to 1×10^{-4} and protein samples (0.15 mg of membrane protein) were incubated with 1.5 nM [^3H]-8-OH-DPAT in a total volume of 0.25 mL of Tris-HCl (50 mM, pH 7.4, 10 mM MgSO₄). Incubations were carried out for 60 min at 25 °C. All assays were terminated by dilution with 5 mL of ice-cold Tris-HCl (10 mM), pH 7.4, and solution were filtered through glass-fiber filters (Whatman GF/F; presoaked in 0.5% polyethyleneimine for 30 min at 25 °C). Filters were then washed three times with 5 mL of ice-cold Tris-HCl (50 mM, pH 7.4), and counted in Hionic-Fluor cocktail (Packard, Groningen, the Netherlands). The corresponding IC₅₀ values were determined with Origin 6.0 software (OriginLab, Northampton, MA) and were used for the calculation of the apparent K_i values with the Cheng-Prusoff equation. See, *Biochem. Pharmacol.* **1973**, 22, 3099-3108.

Example 15: Alpha-1, α_1 Receptor Assays

The in vitro α_1 receptor binding affinities of rhenium coordinated complexes were determined in a competition assay using rat frontal cortex and high-affinity α_1 ligand [^3H]-Prazosin (80Ci/mmol, NEN Life Science Inc., Cambridge, MA). See, *Eur. J. Nucl. Med.* **2002**, 29, 82-87.

The frontal cortex of rat brain was prepared as described above and store at -70 °C until used in the binding assays. Ten concentrations of the nonradioactive rhenium complexes ranging from 1×10^{-10} to 1×10^{-3} and protein samples (0.15 mg of membrane protein) were incubated with 1.5 nM [^3H]-Prazosin in a total volume of 0.25 mL of Tris-HCl (50 mM, pH 7.4, 10 mM MgSO₄). Incubations were carried out for 60 min at 25 °C. All assays were terminated by dilution with 5 mL of ice-cold Tris-HCl (10 mM), pH 7.4, and solution were filtered through glass-fiber filters (Whatman GF/F; presoaked in 0.5% polyethyleneimine for 30 min at 25 °C). Filters were then washed three times with 5 mL of ice-cold Tris-HCl (50 mM, pH 7.4), and counted in Hionic-Fluor cocktail (Packard, Groningen, the Netherlands). The corresponding IC₅₀ values were determined with Origin 6.0 software (OriginLab, Northampton, MA) and were used for the calculation of the apparent K_i values with the Cheng-Prusoff equation. See, *Biochem. Pharmacol.* **1973**, 22, 3099-3108.

Example 16: Sigma-1, σ_1 Receptor Assays

The in vitro σ_1 receptor binding affinities of rhenium coordinated complexes were determined in a competition assay using rat frontal cortex and high-affinity σ_1 ligand [^3H]-(+)-pentazocine (28Ci/mmol, NEN Life Science Inc., Cambridge, MA). See, *Mol.*

5 *Neuropharmacol.* **1993**, 3, 117-126.

The membranes were prepared from guinea pig brain (minus cerebellum) as described above and stored at -70°C . Twelve concentrations of the nonradioactive rhenium complexes ranging from 1×10^{-11} to 1×10^{-3} and protein samples (0.15 mg of membrane protein) were
10 incubated with 5 nM [^3H]-(+)-pentazocine in a total volume of 0.25 mL of Tris-HCl (50 mM, pH 8.0). Incubations were carried out for 120 min at 25°C . All assays were terminated by dilution with 5 mL of ice-cold Tris-HCl (10 mM), pH 8.0, and solution were filtered through glass-fiber filters (Whatman GF/F; presoaked in 0.5% polyethyleneimine for 30 min at 25°C). Filters were then washed three times with 5 mL of ice-cold Tris-HCl (50 mM, pH 8.0),
15 and counted in Hionic-Fluor cocktail (Packard, Groningen, the Netherlands). The corresponding IC_{50} values were determined with Origin 6.0 software (OriginLab, Northampton, MA) and were used for the calculation of the apparent K_i values with the Cheng-Prusoff equation. See, *Biochem. Pharmacol.* **1973**, 22, 3099-3108.

20 **Example 17: σ_2 Receptor Binding Assays**

Rat liver membranes were prepared from male Sprague-Dawley rat livers as previously described (*Eur. J. Pharmacol.- Mol. Pharmacol. Sect.* **1994**, 268, 9-18). The in vitro σ_2 receptor binding affinities of rhenium coordinated complexes were determined in a competition assay using rat livers and [^3H]-DTG (31Ci/mmol, NEN Life Science Inc.,
25 Cambridge, MA) as radioligand in the presence of 10 μM 1-pyrrolidinyethyl 3,4-dichlorophenylacetate oxalate (ACT915 oxalate) to mask σ_1 receptors (*Bioorg. & Med. Chem. Lett.* **2000**, 10, 17-18). Competition assays were performed with twelve concentrations of the nonradioactive rhenium complexes ranging from 1×10^{-10} to 1×10^{-3} and protein samples (0.15 mg of membrane protein) in a total volume of 0.25 mL of Tris-HCl (50 mM, pH 8.0)
30 for 120 min at 25°C . All other manipulations and data analysis were performed as described vide supra for the σ_1 -receptor assays.

Example 18: In-Vivo Tumor Uptake

To study the tumor uptake of radiolabeled metal complexes, *in vivo*, biodistribution experiments at 1 h after their administration were carried out in C57Bl6 male mice with palpable B16 melanoma nodules and male nude mice bearing DU145 human prostate carcinoma in the hind limb.

The biodistribution data including tumor/nontumor (T/NT) ratios for selected organs are summarized in Table 1 and 2 as percentage injected dose per gram (% ID/g).

Example 19: Determination of Lipophilicity and pK_a Values.

The lipophilicity and pK_a values of all complexes were determined using HPLC methods described previously (Stylli, C.; Theobald, A. E. Determination of Ionization Constants of Radiopharmaceuticals in Mixed Solvents by HPLC. *Appl. Radiat. Isot.*, **1987**, 38, 701-708; Johannsen, B.; Scheunemann, M.; Spies, H.; Brust, P.; Wober, J.; Syhre, R.; Pietzsch, H.-J. Technetium(V) and Rhenium(V) Complexes for 5-HT_{2A} Serotonin Receptor Binding: Structure-Affinity Considerations. *Nucl. Med. Biol.*, **1996**, 23, 429-438; and Johannsen, B.; Berger, R.; Brust, P.; Pietzsch, H.-J.; Scheunemann, M.; Seifert, S.; Spies, H.; Syhre, R. Structural Modification of Receptor-Binding Technetium-99m Complexes in Order to Improve Brain Uptake. *Eur. J. Nucl. Med.* **1997**, 24, 316-319). Log *P*, log *D*_(pH 7.4) and pK_a values were determined on a Perkin-Elmer HPLC system 1020 using a reversed phase PRP-1 column (250 x 4.1 mm; 10 μm; Hamilton) run under isocratic conditions with a flow rate of 1.5 mL/min at room temperature. The mobile phase was acetonitrile:phosphate buffer (0.01 M), 3:1, v/v, with the aqueous buffer adjusted to the desired pH between 3 and 11. The capacity factor (*k'*) was calculated for each determination (Braumann, T.; Grimme, L. H. Determination of Hydrophobic Parameters for Pyridazinone Herbicides by Liquid-Liquid Partition and Reversed-Phase High-Performance Liquid Chromatography. *J. Chromatogr.* **1981**, 206, 7-15; El Tayer, N.; van der Waterbeemd, H.; Testa, B. Lipophilicity Measurements of Protonated Basic Compounds by Reversed-Phase High-Performance Liquid Chromatography. II. Procedure for the Determination of a Lipophilic Index Measured by Reversed-Phase High Performance Liquid Chromatography. *J. Chromatogr.* **1985**, 320, 305-312; and Minick, D. J.; Frenz, J. H.; Patrick, M. A.; Brent, D. A. A Comprehensive Method for Determining Hydrophobicity Constants by Reversed-Phase High-Performance Liquid Chromatography. *J. Med. Chem.*, **1988**, 31, 1923-1933) and the partition coefficient at a given

pH (D or $\log D$) were calculated from the equation: $\log D = a \log k' + b$ where the parameters a and b are predetermined using standard amines. The fitted points of inflection from the sigmoidal $D_{\text{HPLC}}/\text{pH}$ profiles permit calculation of the $\text{p}K_{\text{HPLC}}$ (Stylli, C.; Theobald, A. E. Determination of Ionization Constants of Radiopharmaceuticals in Mixed Solvents by HPLC. *Appl. Radiat. Isot.*, **1987**, 38, 701-708). The aqueous ionization constants $\text{p}K_a$ were calculated from the $\text{p}K_{\text{HPLC}}$ values after correction with a predetermined correction factor obtained using standard amine compounds. Log P values of the neutral complexes were estimated from the respective upper plateau of the sigmoidal $\log D/\text{pH}$ curve in the alkaline range.

10

Example 20 Emopamil Binding Protein (EBP) Binding Assay:

Guinea-pig liver membranes-homogenates are prepared following the procedure described by Christina Zech et al (European Journal of Pharmacology-Molecular Pharmacology section, 208: 119-130 (1991) and Fabian F. Moebius et al (Molecular Pharmacology 43: 139-148, 1993). The binding assays can be performed following the procedure described in the above two references. Briefly, in a total volume of 1.0 mL buffer (containing 0.1 w/v digitonin, 10 mM tris-HCl, 0.1 mM PMSF, pH 7.4) are suspended 0.03-0.04 mg of guinea-pig liver microsomal membranes, 0.5 nM (\pm)- ^3H emopamil, the reference drug or Re-complex (in concentration's ranging from 10^{-3} M to 10^{-12} M). After incubation at room temperature for 1-2 hr, the binding is terminated by the addition of 3.0 mL of ice-cold buffer (10% w/v PEG 6000, 10 mM Tris-HCl, 10 mM MgCl_2) pH 7.4 and vacuum filtration through GF/F filters that are presoaked in PEI (0.5% for 20 min). The filters are then washed with an additional 3.0 mL buffer and placed in vials. Following addition of 10.0 mL scintillation liquid, (Hionic-Fluor cocktail, Packard, Groningen, the Netherlands) the amount of ^3H emopamil bound to the membranes is determined and can be plotted against the concentration of the Re-complex or drug reference. The corresponding IC_{50} values can be determined with Origin 6.0 software (OriginLab, Northampton, MA) and are used for the calculation of the apparent K_i values using the Cheng-Prusoff equation (Cheng, Y.; Prusoff, W. H. *Biochem. Pharmacol.* 22, 3099-3108, 1973).

30

Example 21: Ca^{+2} channel binding Assay:

The Ca^{+2} channel affinity for the reference drug or Re-complexes can be determined by the procedure described by Francesco Berardi et al (Bioorganic & Medicinal Chemistry, 9: 1325-

1335, 2001). Briefly, rat brain membrane-preparation can be obtained by the procedure described by Ian J. Reynolds et al (J. Pharmacology and Experimental Therapeutics, 237(3): 731-738, 1986). The 0.05 to 0.1 mg of brain-membranes so obtained are suspended in a total volume of 1.0 mL of 50 mM Hepes buffer pH 7.4, along with 0.2 nM [³H]-
5 desmethoxyverapamil and the reference drug or Re-complex (in concentration's ranging from 10⁻³ M to 10⁻¹² M). After incubation at room temperature for 1 hr, the assay is terminated by rapid filtration on GF/F filters that are presoaked in PEI (0.5%) and washed twice with 1.0 mL of ice-cold buffer. The filters are placed in scintillation vials and following addition of 10.0 mL scintillation liquid, (Hionic-Fluor cocktail, Packard, Groningen, the Netherlands) the
10 amount of [³H]- desmethoxyverapamil bound to the membranes is determined and can be plotted against the concentration of the Re-complex or drug reference. The corresponding IC₅₀ values can be determined with Origin 6.0 software (OriginLab, Northampton, MA) and are used for the calculation of the apparent K_i values using the Cheng-Prusoff equation (Cheng, Y.; Prusoff, W. H. Biochem. Pharmacol. 22, 3099-3108, 1973).

15

Example 22 Preparation of Ligand 24: *N,N'*-Bis-[2-(4-methoxy-benzylsulfanyl)-ethyl]-*N*-[3-(4-phenyl-piperidin-1-yl)-propyl]-ethane-1,2-diamine.

Ligand 24 was prepared by the synthetic procedure depicted in Scheme III.

20 ¹H NMR (CDCl₃): 7.34-7.15 (9H,m, Ar), 6.9-6.75 (4H,d, Ar), 3.77 (6H, br-s, OCH₃), 3.65(4H, br-s, CH₂-Ph), 3.02(3H, m, CH₂), 2.88-2.7 (3H, m, CH₂), 2.67-2.25 (16H,m, CH₂), 2.2-1.9 (5H,m, CH₂). C₃₆H₅₁N₃O₂S₂: Exact Mass: 621.34; MassSpec (ESI⁺): 622.2 (M+H⁺)

Example 23 Preparation of Ligand 25: 2-[[3-(Methyl-phenethyl-amino)-propyl]-(2-tritylsulfanyl-ethyl)-amino]-*N*-(2-tritylsulfanyl-ethyl)-acetamide.
25

Ligand 25 was prepared by a synthetic procedure depicted in Scheme 1 in which *N*-methyl *N*-(2-phenylethyl)amine is used as a nucleophile in place of the 4-substituted piperidine in step (ii).

30 ¹H NMR (CDCl₃): 7.51(1H,t), 7.44-7.31 (12H, m, Ar), 7.28-7.11 (23H,m, Ar), 3.01 (2H, quart, CH₂-Ar), 2.82 (2H,s, CO- CH₂), 2.699(2H,m, CH₂), 2.53 (2H,m, CH₂), 2.45-2.3 (6H, m, CH₂), 2.295-2.22 (4H,m, CH₂), 2.19 (3H,m, CH₃), 1.488 (2H,m, CH₂). C₅₆H₅₉N₃OS₂: Exact Mass: 853.41; MassSpec. (ESI⁺): 854.8 (M+H⁺)

Example 24 Preparation of Ligand 26: *N*-[2-(4-Methoxy-benzylsulfanyl)-ethyl]-2-[[2-(4-methoxy-benzylsulfanyl)-ethyl]-[5-(4-phenyl-piperidin-1-yl)-pentyl]-amino}-acetamide.

was prepared by the synthetic procedure depicted in Scheme IV.

5

¹H NMR (CDCl₃): 7.77(1H,m), 7.4-7.1 (8H,m, Ar), 6.9-6.75 (4H,d,Ar), 3.58-3.55(6H,br-s, OCH₃), 3.66 (2H,s, CH₂-Ph), 3.63 ((2H, s, CH₂-Ph), 3.42 (2H, q, CH₂), 3.05 (1H, m, CH), 3.022 (2H, s, CO-CH₂), 2.7-2.3 (10H, m CH₂), 2.2-1.95 3H, m, CH₂), 1.95-1.7 (3H, m CH₂), 1.6-1.19 (7H, m, CH₂). C₃₈H₅₃N₃O₃S₂: Exact Mass = 663.35; MassSpec (ESI⁺): 664.13 (M+H)⁺

10

Example 25: Re complex of ligand 24 (Re-24).

The complex was synthesized using a procedure similar to that described for Re-15 using ligand-24 obtained as described in Scheme III.

15

¹H NMR (CDCl₃): 7.4-7.15 (5H, m, Ar), 4.3-4.0 (3H, m, CH₂), 4.0-3.7 (2H, m, CH₂), 3.7-3.5 (1H, m, CH), 3.5-3.15 (4H, m, CH₂), 3.15-2.85 (4H, m, CH₂), 2.75 (1H, dd, CH), 2.65-2.3 (3H, m, CH, CH₂), 2.25-1.95 (4H, m, CH₂), 1.94-1.78 (4H, m, CH₂), 1.77-1.66 (1H, m, CH). C₂₀H₃₂N₃OReS₂: Exact Mass = 581.15; MassSpec (ESI⁺): 582.32 (M+H)⁺

20

Example 26 Re complex of ligand 25 (Re-25).

The complex was synthesized using a procedure similar to that described for Re-15 using ligand-25

¹H NMR (CDCl₃): 7.4-7.1 (5H, m, Ar), 4.539 (1H, m, CH), 4.366 (1H, d, CO-CH_a), 4.072 (1H, m, CH), 3.924 (1H, d, CO-CH_b), 3.786 (1H, m, CH), 3.491 (1H, m CH), 3.385-3.0 (4H, m, CH₂), 2.9-2.7 (3H, m, CH₂), 2.68-2.54 (2H, m, CH₂), 2.322 (3H, s, CH₃), 1.827 (2H,m, CH₂), 1.55 (1H, ddd, CH).

25

C₁₈H₂₈N₃O₂ReS₂: Exact Mass = 569.12; MassSpec (ESI⁺): 570.06 (M+H)⁺.

Example 27: Re complex of ligand 26 (Re-26).

The complex was synthesized using a procedure similar to that described for Re-15 using ligand-26 which was obtained as described in Scheme IV.

30

^1H NMR (CDCl_3): 7.4-7.15 (5H, m, Ar), 4.655 (1H, d, CO-CH_a), 4.59 (1H, m, CH), 4.2-3.84 (3H, d+m, CO-CH_b , CH_2), 3.7-3.14 (5H, m, CH_2), 3.14-2.95 (2H, bt-d, CH_2), 2.96-2.74 (1H, dd, CH), 2.62-2.3 (3H, m, CH_2), 2.2-1.95 (2H, ddd, CH_2), 1.95-1.72 (8H, m, CH_2), 1.7-1.5 (3H, m, CH, CH_2).

5 $\text{C}_{22}\text{H}_{34}\text{N}_3\text{O}_2\text{ReS}_2$: Exact Mass = 623.16; MassSpec (ESI^+): 624.01 ($\text{M}+\text{H}$) $^+$.

REST OF THIS PAGE INTENTIONALLY LEFT BLANK

10

Table 1. In-vitro Receptor Affinity, pK_a and Lipophilicity of Rhenium complexes for various receptors

Compound	σ_1 k _i (μ M)	σ_2 k _i (μ M)	α_i k _i (μ M)	5HT _{1A} k _i (nM)	pK _a (Corrected)	k' (Max)	k' (pH=7.4)
Re-15	0.547	0.136 \pm 0.022	0.322 \pm 0.061	589 \pm 70	8.34	160	60
Re-16	4.83	0.336 \pm 0.07	0.048 \pm 0.009	4.5 \pm 0.4	8.09	117	57
Re-18	2.96	0.528 \pm 0.111	0.980 \pm 0.18	N.D.	7.26	37.5	29.7
Re-21	0.553	0.0846 \pm 0.0079	0.039 \pm 0.004	55.7 \pm 8.3			
Re-22	5.511	4.707 \pm 0.986	N.D.	N.D.			
Re-24	0.0203 \pm 0.0015	0.0680 \pm 0.0032	0.4236 \pm 0.0553	423 \pm 70			
Re-25	3.652 \pm 0.542	0.351 \pm 0.0155	2.476 \pm 0.903	329 \pm 27			
Re-26	0.0347 \pm 0.0018	0.0483 \pm 0.0067	0.125 \pm 0.0261	707.6 \pm 98.5			

N.D. = not determined

Table 2: One Hour Biodistribution of ^{99m}Tc -15 in subcutaneously transplanted tumors in mice

Organs	Human Prostate CA (DU145)		Melanoma (B16/F0)	
	%ID/g	S.D.	%ID/g	S.D.
Blood	0.31	0.01	0.44	0.08
Heart	1.82	0.22	1.87	0.42
Liver	12.06	2.22	10.23	1.25
Lung	9.96	0.56	15.60	2.69
Muscle	1.06	0.14	0.90	0.06
Kidney	7.92	1.69	7.66	2.28
Spleen	7.56	1.28	5.95	1.07
Brain	0.51	0.06	0.48	0.1
Intestine	20.94	15.56	14.38	8.87
Stomach	5.26	2.16	6.81	2.33
Skin	1.76	0.21	1.21	0.45
Tumor	2.46	0.28	3.18	0.56
Tumor/Blood	7.93	0.91	7.47	2.48
Tumor/Muscle	2.33	0.23	3.57	0.76
Tumor/Liver	0.21	0.03	0.21	0.07
Tumor/Lung	0.25	0.02	0.31	0.07


5

The present invention has been described in detail. However, it will be appreciated that those skilled in the art may make modifications and improvements within the scope of the invention. For example, the pharmacore group may be linked to a carbon atom of the chelating ligand instead of to a nitrogen atom.

10

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound capable of binding a metal ion, the compound according to the formula:



wherein:

R_D is independently selected at each occurrence from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, hydroxy, amino, halogen, cyano, nitro, optionally substituted alkoxy, optionally substituted alkoxyalkyl, optionally substituted mono and dialkyl amino, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heteroalicyclic groups;

Z_1 and Z_2 are independently selected from CH, CR_D , and N;

p is selected from integers between 0 and 5;

q is selected from integers between 0 and 10;

R is selected from hydrogen, $C(O)O(R_3)$, or $C(O)NH(R_3)$;

R_3 represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and optionally substituted cycloalkyl;

E represents an oxo group or two hydrogen atoms; and


X is a linking group comprising a backbone chain having 1 to 8 atoms, the backbone chain can optionally include ester, amide, ether or thioether linkages in the backbone chain;

wherein the substituents are selected from the group consisting of halogen; cyano; hydroxyl; nitro; azido; alkanoyl; carboxamido; C_1 - C_{12} alkyl groups; C_2 - C_{12} alkenyl and C_2 - C_{12} alkynyl groups; C_1 - C_{12} alkoxy groups; aryloxy groups; C_1 - C_{12} alkylthio groups; C_1 - C_{12} alkylsulfinyl groups; C_1 - C_{12} alkylsulfonyl groups; C_1 - C_{12} aminoalkyl groups; carbocyclic aryl groups having 6 or more carbons; arylalkyl having 1 to 3 separate or fused rings and from 6 to 18

carbon ring atoms; arylalkoxy having 1 to 3 separate or fused rings and from 6 to 18 carbon ring atoms; or a heteroaromatic or heteroalicyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O or S atoms;

and wherein X is a lower alkyl group having from 1 to 8 atoms in the backbone, an ether group having 3 to 8 atoms in the backbone, an ester group having 4 to 8 atoms in the backbone, a thioether group having 3 to 8 atoms in the backbone, or an amido group having 4 to 8 atoms in the backbone.

2. A compound capable of binding a metal ion, the compound according to the formula:



wherein:

A is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted heteroaralkyl, optionally substituted heteroaryl, and -X-Y;

R is selected from hydrogen, C(O)O(R₃), or C(O)NH(R₃);

R₃ represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and optionally substituted cycloalkyl;

E represents an oxo group or two hydrogen atoms;

X and the substituents are as defined in claim 1 and

Y is a group capable of chelating to at least one metal ion.

3. The compound of claim 1 or claim 2, wherein X is a lower alkyl group having from 1 to 8 atoms in the backbone, an ether group having 3 to 8 atoms in the backbone,

an ester group having 4 to 8 atoms in the backbone, a thioether group having 3 to 8 atoms in the backbone, or an amido group having 4 to 8 atoms in the backbone.


4. The compound of claim 1 or claim 2, wherein X is of the formula $-(CH_2)_m-$ C(O)NH-, wherein m is between 0 and 5, or X is an α,ω -alkylene group wherein the alkylene group has between 1 and 10 carbon atoms and between 0 and 3 oxygen or sulfur atoms in the alkylene chain.

5. A ligand substantially as hereinbefore described with reference to any one of Examples 1 to 5, 22, 23 or 24.

6. A neutral or cationic complex comprising a metal ion and a compound according to any one of claims 1 to 4 or a ligand according to claim 5.

7. The neutral or cationic complex of claim 6, wherein the metal ion is one or more isotopes of a metal selected from the group consisting of technetium, rhenium, yttrium, copper, gallium, indium, bismuth, platinum and rhodium.

8. A complex of claim 6, wherein the complex is of the formula:



wherein:

M is one or more isotopes of technetium or rhenium;

A is selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted heteroalicyclic, optionally substituted heteroaralkyl, optionally substituted heteroaryl, and -X-Y;

R is selected from hydrogen, $C(O)O(R_3)$, or $C(O)NH(R_3)$;

R_3 represents hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted aralkyl, and optionally substituted cycloalkyl;

E represents an oxo group or two hydrogen atoms; wherein

X and the substituents are as defined in claim 1 and

Y is a group capable of chelating to at least one metal ion.

9. A method for in-vivo or in-vitro imaging of at least one tumor comprising the steps of:

providing a radiolabeled complex comprising a compound of any one of claims 1 to 4, a ligand of claim 5 and a metal ion or a metal complex of any one of claims 6 to 8

contacting the tumor(s) with the radiolabeled metal complex; and

making a radiographic image to visualize the tumor(s).

10. A method for in-vivo or in-vitro imaging of at least one tissue expressing one or more proteins or receptors for which radiolabeled complexes have affinity, the method comprising the steps of:

providing a radiolabeled complex comprising a compound of any one of claims 1 to 4, a ligand of claim 5 and a metal ion or a metal complex of any one of claims 6 to 8;

contacting the tissue(s) expressing the receptors with the radiolabeled metal complex; and

making a radiographic image to visualize the tissue(s).

11. The method of claim 10, wherein the tissue is part of the central nervous system or nervous system.

12. The method of claim 11, wherein the tissue is brain tissue expressing the protein or receptors.

13. The method of claim 10, wherein the tissue is a tumor.

14. Use of a cytotoxic metal complex comprising a metal ion and a compound of any one of claims 1 through 4, a ligand of claim 5 or a metal complex according to anyone of claims claim 6 to 8 for the manufacture of a medicament for the treatment of cancer.

15. A method for the treatment of cancer comprising administering to a patient a compound of any one of claims 1 through 4, a ligand of claim 5 or a metal complex according to anyone of claims claim 6 to 8

16. A method of in-vivo or vitro-inhibiting a protein or receptor in a tumor comprising the steps of:

providing a metal complex comprising a metal ion and a compound of any one of claims 1 to 4, a ligand of claim 5 or a metal complex according to any one of claims 6 to 8; and contacting the tumor(s) with the metal complex.

17. The method of any one of claims 9 to 13, 15 or 16, wherein the metal ion is one or more isotopes of a metal selected from the group consisting of technetium, rhenium, yttrium, copper, gallium, indium, bismuth, platinum and rhodium.


18. The method of any one of claims 9 to 13, 15 or 16, wherein the metal ion is technetium-99m or one or more isotopes of rhenium.

19. The method of any one of claims 9 to 13, 15 or 16, wherein the tumor(s) or cancer is selected from the group consisting of neoplasm(s), carcinoma(s), and melanoma(s).

20. The method of any one of claims 9 to 13, 15 or 16, wherein the tumor(s) or cancer is selected from the group consisting of prostate carcinoma, breast carcinoma, lung carcinoma, renal carcinoma, colon carcinoma, glioblastoma, neuroblastoma, sarcoma, or a combination thereof.

1/13


FIG. 1



2/13


FIG. 2

Sigma2 Binding Affinities of Re-Complexes




3/13

FIG. 3




4/13

FIG. 4




5/13

FIG 5



6/13


FIG 6



7/13


FIG 7

Sigma2 Binding Affinities of Re25 and Re24




8/13

FIG 8




9/13

FIG 9




10/13

FIG 10




11/13

FIG 11



12/13

FIG 12



13/13

FIG 13

